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Abstract 
Type 2 diabetes (T2D) is a common complex metabolic disease and represents one of the 
main health-care problems worldwide. Only 10-12% of T2D heritability is explained by genetic 
variability, while many environmental factors  have a critical role in the onset of the disease; for 
these reasons, an important aspect to take into account in this field is the interaction among the 
different risk factors. 
The aim of this thesis is to apply an integrative analysis of genetic and epigenetic data in 
order to identify new molecular mechanisms and interactions at the basis of T2D considering an 
Italian population. 
First we performed a T2D case-control study on 1352 individuals at genome-wide level using 
Illumina technology. T2D patients with at least one complication were compared first with the 
healthy control group and then with centenarians (who never developed the disease), applying the 
“extreme phenotypes” approach. In the meantime, we conducted a methylation analysis at gene 
candidate level on 229 diabetic patients and 219 controls. For this analysis we considered three 
different regions of TCF7L2 gene. Finally, we applied two different approaches (one based on some 
phenotypic traits, the genotype of rs7903146 and methylation levels of 5 CpG sites of TCF7L2 gene 
and the second on DNA methylation of few genes called "epigenetic little clock") in order to develop 
a disease predictor model able to differentiate T2D patients group from the control group. 
In the genetic analyses we identified five genes with multiple associated signals in the 
comparison between diabetes individuals and controls: MS4A14 and THSD4 genes, that have never 
been related to T2D, and we confirmed association variants in DNHD1, ELMOD1 DLC1 genes. 
Then, considering the “extreme phenotypes”, we compared diabetic patients with centenarians and 
we found four genes with more than one associated SNP: FAM13A, TCF7L2, APBB2 and MGLL 
genes, the last two have never been associated to T2D. Finally, we identified the genes with multiple 
associated variants that were present in both comparisons. We identified three key genes TMEM108, 
UPP2 and TCF7L2 for T2D . 
In methylation analysis performed on TCF7L2 gene, we reported an association between 
methylation levels of two CpG sites in intron 3 with T2D in our population and we demonstrated that 
methylation levels of four CpG sites (two in promoter region and two in intron 3) are strongly 
influenced by the genotype of the most T2D related variant, rs7903146. 
We developed a disease prediction model based on a linear regression model of the strongest 
diabetes related variant (rs7903146 of TCF7L2 gene), phenotypic trait (BMI, sex, age) and 
methylation levels of 5 CpG sites in intron 3 region of TCF7L2 gene that would be able to correctly 
classify 63% of subjects. Finally, we applied an epigenetic little clock to diabetic patients that, 
surprisingly, did not show an acceleration of epigenetic age. 
The overall results highlighted: 1) the genetic variants associated to an increase susceptibility 
to T2D thanks to the exploitation of a group of Italian centenarians who never developed the disease, 
2) the relation between DNA methylation and the genotype of TCF7L2-rs7903146; 3) a first example 
of a mathematical model for the prediction of the disease 4) that external/environmental factors (such 
as pharmacological treatment) may influence the epigenetic age of diabetic patients considered in our 
study.  
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1 Introduction 
The increase of people affected by type 2 diabetes (T2D) represents one of the most 
important health-care problems worldwide and this phenomenon will increase in the next decades in 
industrialized and developing countries (International Diabetes Federation, 8th edition 2017). This 
raise is due to the aging of the populations and to the increasing prevalence of obesity (Danaei et al. 
2011). T2D is a common complex metabolic disease characterized by an impaired glucose 
metabolism due to insulin resistance of peripheral tissues. Several risk factors are involved in T2D 
onset, such as age, obesity and low physical activity (World Health Organization 2004). Among the 
risk factors the genetic heritability plays a key role in the onset of the disease. In fact, 40% of 
diabetic patients present a family history of diabetes; nevertheless, the alimentary habits, the physical 
activity and “healthy” life style, can delay or avoid the onset of the disease. Actually, an important 
aspect to take into account is the interaction among the different risk factors. 
1.1 Genetics and T2D 
The first linkage analysis studies were performed in the ’90s and identified two genes, calpain 
10 (CAPN10) and transcription factor 7-like 2 (TCF7L2) associated with T2D (Hanis et al. 1996) 
(Duggirala et al. 1999). Subsequently, several candidate gene studies have been conducted, focusing 
on genes potentially involved in pathways affected by T2D, such glucose metabolism, insulin 
secretion and signalling, and lipid metabolism. By means of this strategy a number of genes were 
identified: peroxisome proliferator-activated receptor gamma (PPARG), insulin receptor substrate 1 
(IRS1) and IRS-2, potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11), 
Wolfram syndrome 1 (wolframin) (WFS1), HNF1 homeobox A (HNF1A), HNF1 homeobox B 
(HNF1B) and HNF4A (Gaulton et al. 2008). 
Using microarray technology, Genome-wide association studies (GWAS) have been 
conducted and confirmed several T2D-associated loci and identified new ones e.g. HHEX/IDE and 
SLC30A8 genes (Sladek et al. 2007) (Scott et al. 2007) (Zeggini 2007) (Diabetes Genetics Initiative 
of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical 
Research et al. 2007), CDKN2A/2B, and the intronic region of CDKAL1 and IGF2BP2 (Pal and 
McCarthy 2013). 
Finally, in order to increase sample size for the identification of novel associated loci, two 
meta-analysis studies have been performed. In the first one, the DIAbetes Genetics Replication And 
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Meta-analysis (DIAGRAM) study, including 10,000 subjects in the “scan” step, and 53,000 
individuals in the replication phase, six novel loci have been identified (JAZF1, CDC123-CAMK1D, 
TSPAN8-LGR5, THADA, ADAMTS9 and NOTCH2) (Zeggini et al. 2008). In the second meta-
analysis study (DIAGRAM+), performed on more than 101,000 individuals, 12 additional loci have 
been associated to T2D (Voight et al. 2010). 
1.2 Epigenetics and T2D 
The term “epigenetics” refers to heritable modifications in gene expression that do not 
modify nucleotide sequence. Epigenetic mechanisms include DNA methylation, histone acetylation 
and non-coding RNAs, and they are used to modulate gene expression in response to environmental 
stimuli. The epigenetic profile can persist lifelong and can be transmitted to descendants for up to 2-3 
generations (Skinner 2011). Recently, evidences of possible epigenetic involvement in the 
pathogenesis of diabetes have emerged. Several authors have hypothesized the existence of a 
metabolic program influenced by environmental conditions and genetic predisposition that 
contributes to the development of diabetes. It is known that the intrauterine and early infancy 
environment can modulate the risk of chronic, late-onset diseases like T2D in humans and animal 
models (Seki et al. 2012). In fact, several evidences suggest that environmental and nutritional 
exposure in prenatal/neonatal phases modulate the fetal epigenetic profile and can contribute to risk 
of developing metabolic disorders including type 2 diabetes (Vaiserman 2017). Epigenetic 
mechanisms such as DNA methylation and histone acetylation alter the expression of genes. There 
are numerous studies that have shown association between gene expression and methylation with 
diabetic pathology at the level of the various organs. 
The first epigenome-wide study on T2D was performed on DNA from peripheral blood, and 
differentially methylated regions (DMRs) have been associated to T2D in particular in GWAS 
susceptibility loci (Toperoff et al. 2012). More recently, three independent studies have found a 
differential methylation at a CpG site in TXNIP (Chambers et al. 2015) (Florath et al. 2016) 
(Kulkarni et al. 2015). Moreover, a study conducted on pancreatic islets identified more than 800 
genes showing DMRs between diabetics and controls, including genes already known to be 
associated with T2D like TCF7L2, FTO and KCNQ1. 
All these results demonstrate how close is the linkage between genetics and epigenetics in the 
study of a complex and multifactorial diseases like T2D. 
3 
 
Although in the last decade there has been a dramatic explosion of genetic studies, thanks to 
technological advancement and innovative analytical methods, only 10-15% of heritability has been 
explained so far. Numerous efforts have been made in order to explain the “missing heritability”. 
This main obstacle is the small effect of every single variant in the onset of the disease, together with 
the heterogeneous phenotype of T2D and the coexistence of several risk factors. 
1.3 Extreme phenotypes 
Complicated T2D represents the most severe form of the disease. All the complications share 
a vascular component, indicating that endothelial damage is a critical point for the progression of 
diabetes. T2D complications are also influenced by genetic components as demonstrated in three 
studies that have examined diabetes complications and genetics. Jin and colleagues have showed 
association of polymorphisms in TMEM217 (transmembrane protein), MRPL14 (mitochondrial 
ribosomial protein) and GRIK2 (glutamate receptor) genes with retinopathy (Jin and Liu 2008). 
Another complication of diabetes is nephropathy. In this case an association among rs2268388, 
mapping in ACAC (Acetyl-CoA Carboxylase Alpha) gene, and rs5186, mapping in AGTR1 
(receptor type 1 of angiotensin II) gene, have been described with this complication. The study has 
been performed on 1,158 patients with T2D from the North and the South of India (Shah et al. 2013). 
Finally, Achilli and collaborators have performed an association study between T2D and 
mitochondrial haplogroups. Hypervariable sequences (HVS-I and HVS-II) of mitochondrial DNAs 
were sequenced in 904 healthy and diabetic subjects from the centre of Italy. No significant 
association was found with the disease; however, some haplogroups resulted associated with an 
increased risk of complications. In particular, U3 haplogroup is four times more represented in the 
patients with nephropathy, haplogroup V resulted associated with renal impairment, while 
haplogroups H and H3 were associated to increased risk of neuropathy (Achilli et al. 2011). 
In the last two centuries, life expectancy is enormously increased, especially in the western 
countries (Abbott 2004). In fact at the beginning of XIX century life expectancy at birth was around 
40 years (Abbott 2004), while in 2000-2005 has reached 71,9 years for men and 79,3 years for 
women, with exceptions that overcome the 100 (Candore et al. 2006). This phenomenon is due not 
only to an improvement of socio-economic conditions, but it also has a genetic contribution that 
explain about 25% of the trait (Herskind et al. 1996) (vB Hjelmborg et al. 2006). In fact, different 
studies have showed that longevity is the result of a complex interaction among genetic, 
environmental and stochastics factors (Franceschi et al. 2005). The purpose of the studies performed 
on centenarians is to detect the genetic components that contribute to longevity and healthy aging. 
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Centenarians, in fact, constitute the best model of successful aging (Franceschi et al. 2000), as they 
live much longer than the other members of their birth cohort, largely avoided or postponed the main 
age-related ailments, and maintained good physical and cognitive performances until very old age. 
The successful aging could be defined through the following characteristics: 
- Absence of disability and diseases 
- High-level of cognitive and physical abilities  
- Maintenance of a productive or social activity (Franceschi et al. 2008). 
Centenarians are characterized not only by an extreme longevity, but also through the ability 
to escape or delay the most common age-related diseases, such as cardiovascular diseases and 
diabetes (Franceschi and Bonafè 2003). For this reason, they are also studied for better understanding 
the genetic component involved in the pathologies. Data obtained from a group of Italian 
centenarians suggest that the major age-related modifications occur in metabolic pathways and in 
endocrine functions (Carrieri et al. 2001). It has been also reported that the prevalence of insulin 
resistance is very low in centenarians, moreover despite glucose and insulin concentrations are the 
same, between elderly people and centenarians, the latter show highest glucose uptake, comparable 
to those of middle-age people (Paolisso et al. 1996). Insulin resistance increases during aging up to 
80-90 years. Between 90 and 100 years it is observed a significant decrease in insulin resistance 
(Cevenini et al. 2008). All these data suggest that the energy metabolism has an important role in 
healthy aging (Roth et al. 2004) (Fontana and Klein 2007) (Bonafè and Olivieri 2009). Moreover, it 
has been hypothesized that centenarians, in comparison to elderly general population, have a 
characteristic genetic pattern that preferentially activate an anti-inflammatory response (Salvioli et al. 
2006) (Bonafè and Olivieri 2009) (Candore, Caruso, and Colonna-Romano 2010). Therefore, 
centenarians can be considered a fruitful experimental model to be used for genetic association 
studies in order to pinpoint genetic determinants of health and longevity. 
 
1.4 Disease prediction models 
Prediction model is an important tool in both medical practice and research and it may 
contribute to set up preventive interventions for specific subjects at relatively high risk of developing 
a disease. In fact, to identify subjects at high risk for diabetes is important in term of targeted 
prevention strategies, pharmacological focused treatment and follow up. 
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The initial attempt to create a T2D prediction model was performed in the ‘90s. The first 
study dates back to 1993, and took into account several factors like demographic, anthropometric, 
metabolic and hemodynamic parameters. The sensitivity of this multiple logistic regression model 
was higher (67.7 to 83.3%) respect to impaired glucose tolerance (56.5 to 62.1%); demonstrating that 
models based on different parameters could improve the efficacy of the test (Stern et al. 1993). Later 
on, several models have been developed that considered genetic susceptibility loci. A study 
conducted in Japanese population applied regression methods that included a genetic risk factor in 
combination with their interactions. The authors identified a model based on a Bayes factor approach 
and the LASSO regression method in which nine associated SNPs and clinical factors were 
considered. The authors concluded that the efficacy of their test with an area under the curve (AUC) 
of 0.8085 was accounted mainly by clinical factors rather than genetic variability (Shigemizu et al. 
2014). Very recently, the same analytical method was applied to metabolomics parameters in a 
European population. The prediction of T2D by using this methods was high (AUC=0.81) and when 
the fasting glucose value was included, it rose up to AUC=0.89 (Liu et al. 2017). The last reported 
prediction model for T2D was develop using an analytical platform, the Reverse Engineering and 
Forward Simulation, and took into account several associated biochemical parameters in a 
retrospectivity study. The model accurately predicted progression to T2D (AUC = 0.76) in training 
group, and AUC = 0.78 in validation group samples. 
Although several diabetes-related prediction models have been reported, and despite each 
accuracy seems to be elevate, other efforts will be do in order to found a validated and largely 
accepted prediction model of diabetes. 
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2 Aim of the study 
The aim of this thesis is to apply an integrative analysis of genetic and epigenetic data in 
order to identify new risk factors that can underlie yet unknown or underestimated molecular 
mechanisms at the basis of Type 2 Diabetes considering an Italian population.  
To do this, we decided to evaluate genetic risk factor performing a genome wide association 
on more than 550,000 SNPs using an approach that considers “extreme phenotypes”, i.e. persons 
who never got diabetes in their life, like centenarians, and on the other side, patients with severe 
forms of T2D. We include in our study T2D patients with at least one complication, and centenarians 
as well as healthy controls. 
In order to answer the first aspect of the question (genetic risk factors), we performed 
association analyses of genetic data for both comparisons (T2D VS controls and T2D VS 
centenarians) in order to identify the variants that potentially exert biological functions. 
In order to answer the second aspect of the question (epigenetic risk factors), we considered 
the methylation status of TCF7L2 gene, one of the strongest locus related to T2D, in a subset of 
diabetic patients and healthy controls. We performed the analysis in promoter region and two CpG 
Islands in intron 3 and 3’UTR of the gene, using a MassARRAY technology (Agena Bioscience).  
Finally, we performed an integrated analysis of methylation and genetic results of TCF7L2 
gene in order to investigate a possible interaction between these factors. Based on this hypothesis we 
analysed the methylation status in patients and controls grouped based on the genotype of rs7903146 
variant of TCF7L2. 
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3 Experimental Procedures 
 
3.1 Cohort description 
1,395 subjects from Northern/Central Italy were recruited by the Unit of Diabetology of the 
“National Institute on Health and Science on Aging” (INRCA) of Ancona, Italy; written informed 
consent was obtained from all subjects and T2D diagnosis was assessed according to the American 
Diabetes Association criteria (http://www.diabetes.org/). Subsequently, 614 patients (mean age 65.5 
years) and 781 unrelated controls (mean age 48.4 years; age range 19-85 years) were studied. 
Moreover, 351 centenarians (mean age: 100.4 ± 1.4) have been considered in the genetic study 
(Table 1). 
 
 T2D (n=614) Controls (n=781) Centenarians (n=351) 
Sex (Males/Females) 330/284 419/362 79/272 
Mean Age ± SD (years) 65.5±8.5 48.4±15.2 100.4±1.4 
Table 1 Subjects number, sex, age and BMI are reported. T2D: Type 2 Diabetes, BMI: Body Mass Index, SD: Standard Deviation 
 
A large number of biochemical and endocrinological parameters were collected for all 
individuals. A detailed clinical history was recorded for controls subjects, in order to exclude the 
presence of T2D and of any other overt disease. 
Genome Wide Association Study (GWAS) samples 
282 T2D patients with at least one complication or high level of glycated haemoglobin, 737 
controls and 333 centenarians were included in GWAS. These subjects were genotyped at whole 
genome level according to the procedures described in the following section. 
Gene candidate methylation analysis samples 
Among of cohort previously described, 448 subjects, 229 T2D patients and 219 sex-, age- and 
BMI-matched controls, were selected for methylation analysis of TCF7L2 gene, details are reported 
in table 2. 
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 T2D (n=229) Non diabetics (n=219) 
Gender (Males/Females) 115/114 92/127 
Mean Age (years) 63.8±8.9 56.6±12.3 
Mean BMI (kg/m2) 28.0±3.9 26.9±4.3 
Table 2 Subjects number, sex, age and BMI are reported. BMI: Body Mass Index, SD: Standard Deviation 
 
The analysis was performed at gene region level and the procedure is reported in the 
following section. 
Disease Prediction Models samples 
Logistic regression model based on genotypes, phenotypes and methylation value: the samples 
encompassed in this analysis are the same including in gene candidate methylation analysis.  
Epigenetic Age Prediction “Little clock” samples: 298 healthy subjects from 0 to 100 years was 
included in the training step, in order to test the model. Then, the trained model was applied to 24 
centenarians, 24 centenarians’ offspring, 16 subjects with Down Syndrome and 181 diabetic patients. 
3.2 DNA extraction 
Genomic DNA was extracted from 1,721 whole blood samples using the QIAmp DNA Blood 
Kit (Quiagen, Hilden, Germany) following the manufacture procedure except for the elution step, we 
utilized 100 µl for the first elution and 50 µl for the second one. 
3.3 DNA quantification, normalization and bisulfite treatment 
DNA quantification was obtained with spectrophotometric technology using NanoDrop 1000 
(Thermo Fisher Scientific, Inc. MA, USA). For Illumina array 500 ng of DNA were normalized in 10 
µl; for gene candidate methylation analysis 1000 ng of DNA were normalized in 10 µl. 
1000 ng of genomic DNA was used to bisulﬁte conversion using the EZ DNA Methylation 
Kit (Zymo Research, Orange, CA, USA). Procedure was conducted according to the manufacturer’s 
protocol, except for the conversion step; the conversion cycle was the following: 21 cycles at 95°C 
for 30 seconds and 50°C for 15 minutes. 
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3.4 Genome Wide Association Study 
The genetic characterization at genomic level was performed using Infinium CoreExome-24 
BeadChip (Illumina, Inc, CA, USA), this technology allows to assess the genotyping of more than 
550,000 single nucleotide polymorphisms (SNPs). About 280,000 variants enclose into intronic or 
gene desert region and more than 265,000 loci encompass onto exonic region. This technology is 
based silicon-based array device, BeadChip. This peculiar chip manufacturing allows the 
simultaneous analysis up to 24 samples, which are physically separated within the chip sections. The 
BeadChip substrate contains microwells in which are held the beads attaching to oligonucleotides 
probe sequences. The robustness and measurement precision of this technology is allowed by 
multiple copies of each bead type present in the array; moreover, reproducibility and high-quality of 
genotyping data is obtained with hybridization-based quality controls of each array. The assay 
workflow is outlined in figure 1. 
 
 
Figure 1 Workflow of Infinium HTS Assay 
 
3.5 Gene candidate methylation analysis and Epigenetic Little Clock 
Methylation levels of gene specific regions were assessed using mass spectrometry 
technology (Agena Bio, CA, USA). The EpiTYPER protocol, here utilized, is based on amplification 
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of bisulfite-converted DNA, SAP treatment, following by in vitro retro-transcription and T-specific 
cleavage. The cleaved fragments obtained are than analysed in mass spectrometry. Specific software 
is able to convert detected quantitative mass spectrometry in DNA methylation levels. This 
technology allows to interrogate the methylation status of several CpGs in amplicons of up to 700 
bps length up to 384 samples in the same experiment. In figure 2 are reported the steps of EpiTYPER 
protocol. 
 
Figure 2 Overview on EpiTYPER assay 
Moreover, this methodology is high reproducible and sensible, permitting to detect down to 
5% differences in methylation. In tables 3 and 4 are reported informations of amplified regions for 
methylation analyses of TCF7L2 gene and epigenetic little clock respectively. The design was 
performed using EpiDesigner software (Agena Bio, CA, USA) (https://www.epidesigner.com/). 
 Chromosome Position Gene Region Number of Amplicon Number of CpG 
Promoter Region chr10:114709919-
114710801 
5’UTR 2 30 
CpG Island 43 chr10:114711916-
114712744 
Body (Intron 3) 2 54 
CpG Island 16 chr10:114925323-
114925951 
3’UTR 1 22 
Table 3 Amplified regions using for methylation analyses of TCF7L2 gene. Chromosome positions and CpG Island numbers are reported 
according to GRCh37/hg19 UCSC database. 
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 Chromosome Position Gene Region Number of Amplicon Number of CpG 
ELOVL2 Chr6:11044580-11045153 Promoter 1 16 
CA3 Chr8:86350116-86350532 Promoter 1 6 
LYPD5 Chr19:44324827-44325168 Upstream 1 10 
Table 4 Amplified regions using for methylation analyses of epigenetic little clock genes. Chromosome positions and number of selected 
amplicons are reported according to GRCh37/hg19 UCSC database. 
 
 
3.6 Statistical Analysis 
Genome wide association study: Association analysis was performed using the PLINK 
package v.1.06 by means of a logistic model and adding sex as a covariate. The Manhattan plots 
were calculated using R (package: qqman). Quality controls (QC) were performed on the generated 
data in attempt to avoid the identification of false positive results when searching for loci potentially 
involved in longevity and according to protocols and pipelines described in Anderson et al. 
(Anderson et al. 2010). 
 
Univariate Logistic Regression, Multivariate Logistic Regression, Partial Least Square (PLS) 
regression: regression and both Univariate and Multivariate Logistic Regression have been 
performed in python 2.7 using the module scikit-learn v.0.17.1. 
 
Epigenetic age (EpiAge) estimation: estimation model has been computed using the Linear 
Regression function implemented in python 2.7 within the module scikit-learn v.0.17.1 and the 
regplot function implemented in seaborn v.0.6.0.  
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4 RESULTS AND DISCUSSION 
4.1 Genome Wide Association Study 
Although many efforts have been made to understand the genetic basis of T2D, only a small 
percentage of heritability has been explained so far. The difficulty to detect a strong genetic 
association is due, on one side, to the small effect that each single gene variant has on the phenotype 
and, on the other side, to the complexity of the disease. Both issues can be overcome by adopting a 
new strategy in genetic studies of T2D; the innovative approach here applied is the use of “extreme 
phenotypes”. The basic hypothesis is that most serious clinical manifestations should be associated 
with enrichment in genetic risk variants, and conversely, people who have reached and passed the 
century of life by avoiding or postponing age-associated diseases should be enriched in protective 
gene variants. With this strategy, our group demonstrated by a gene-candidate study that the 
frequency of risk genotypes of rs7903146-T of TCF7L2 is minimal in centenarians and increases 
progressively according to the severity of the disease, showing that centenarians represent a powerful 
an informative control group in association studies on clinical heterogeneity disease like T2D 
(Garagnani et al. 2013). 
GWAS was conducted following the hypothesis of the “extreme phenotypes” in order to 
increase the sensitivity of our study and to identify the variants with a biological function (Garagnani 
et al. 2013) (Giuliani et al. 2017). First of all, 282 diabetic patients with at least one complication and 
773 healthy controls were compared. Then, the same group of diabetic patients (N=282) was 
compared with 334 centenarians. The genetic characterization was obtained by using Illumina array 
(Infinium CoreExome-24 BeadChip Kit) that includes 534,333 SNPs. In order to remove false 
positive associations, Quality controls (QC) were performed according to protocols and pipeline 
described in literature (Anderson et al. 2010) and described in Materials and Methods section. Figure 
3 reports the Manhattan plot performed considering the nominal p-values of the logistic regression 
between diabetic patients and centenarians (Figure 3A) and diabetic patients and controls (Figure 
3B). In the analysis sex has been considered as a covariate. 
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Figure 2 Manhattan plot of all SNPs for the association analysis of two comparisons; A) associated SNPs considering diabetic patients and 
centenarians; B) associated SNPs considering diabetic patients and controls. The x axis shows SNPs according to their chromosomal positions. 
The blue line represents the threshold of p<10-5. 
 
In the comparison of diabetic patients and controls, 245,918 variants have been removed due 
to minor allele thresholds, and then 270,512 variants and 1,382 individuals have passed QC filters. 
Subsequently, 73 variants with p value <10-5 have been detected (table 5). 
 
CHR SNP BP A1 Freq Diab Freq Cent A2 P OR 
8 rs4732756 27664686 A 0.1685 0.09272 G 2.82E-06 1.974 
11 rs7925649 72970776 A 0.1135 0.2046 G 2.96E-06 0.5023 
8 rs4732748 27634064 A 0.1667 0.09205 G 3.41E-06 1.962 
8 rs1729109 13194328 A 0.1119 0.05166 G 3.85E-06 2.283 
11 rs3825020 60184191 G 0.4273 0.3185 A 4.51E-06 1.613 
22 rs5995572 38753311 G 0.03929 0.006311 A 6.04E-06 6.159 
9 rs954124 88563064 A 0.1578 0.251 G 6.54E-06 0.5522 
1 rs11161732 86557967 A 0.531 0.4184 G 8.63E-06 1.564 
8 rs6987111 27600450 A 0.1631 0.09272 C 1.17E-05 1.885 
14 rs4640079 32438841 A 0.3777 0.2742 G 1.34E-05 1.555 
8 rs3779620 27679981 G 0.1684 0.09735 A 1.44E-05 1.855 
22 rs137878 50456791 A 0.3564 0.2623 G 1.90E-05 1.599 
8 rs1671389 13181518 A 0.1046 0.05033 C 1.92E-05 2.165 
16 rs7197624 55110037 A 0.0656 0.02517 G 1.99E-05 2.794 
1 rs12408292 62212822 A 0.3404 0.4417 G 2.18E-05 0.636 
15 rs8032461 71956136 A 0.2465 0.1656 G 2.38E-05 1.675 
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4 rs4602536 184298419 G 0.4592 0.357 A 2.76E-05 1.533 
13 rs1757889 76923323 G 0.3333 0.4364 A 2.83E-05 0.647 
11 rs11605196 6524072 C 0.2571 0.1722 A 3.00E-05 1.621 
8 rs7845862 38471714 G 0.3227 0.2311 A 3.31E-05 1.571 
2 rs10490411 56772337 G 0.4982 0.394 A 3.49E-05 1.498 
12 rs167769 57503775 A 0.3546 0.2616 G 3.55E-05 1.557 
8 rs17652171 113662583 C 0.1613 0.2437 A 3.60E-05 0.5751 
15 rs1995334 71949248 A 0.2429 0.1642 G 3.68E-05 1.657 
5 rs2052481 80282815 C 0.4078 0.3093 A 3.69E-05 1.526 
2 rs16862115 174680319 A 0.266 0.1841 G 3.89E-05 1.624 
11 rs11603869 6541225 G 0.2766 0.1914 C 4.39E-05 1.589 
15 rs338364 68173921 G 0.3652 0.2695 A 4.57E-05 1.523 
16 rs12934314 49822940 G 0.3812 0.2834 A 4.68E-05 1.501 
2 rs6742210 40615520 A 0.3865 0.4901 G 4.89E-05 0.6678 
3 rs13326165 52532118 A 0.1472 0.2305 G 4.94E-05 0.5795 
11 rs2233253 60157166 G 0.3617 0.2695 A 5.24E-05 1.541 
9 rs17086 124125520 G 0.539 0.4397 A 5.59E-05 1.498 
6 rs9388238 123731285 A 0.2394 0.1598 G 5.63E-05 1.618 
11 rs4938941 60173360 A 0.3617 0.2702 G 5.70E-05 1.537 
5 rs7728693 77142481 G 0.3227 0.4205 A 6.34E-05 0.6574 
16 rs1870038 55930518 A 0.1897 0.2762 G 6.43E-05 0.6126 
1 rs2902103 177341802 C 0.1543 0.09139 A 6.64E-05 1.791 
6 rs3823036 99284532 G 0.1809 0.2656 A 6.71E-05 0.6059 
15 rs4777035 68605169 G 0.5071 0.4079 A 6.76E-05 1.489 
8 rs1671382 13185325 A 0.1578 0.0947 G 6.79E-05 1.792 
9 rs7029374 23358448 A 0.3227 0.2364 G 6.81E-05 1.554 
1 rs12091015 172019718 A 0.5195 0.4232 G 6.93E-05 1.497 
13 rs1164519 76899888 G 0.4663 0.3695 A 6.97E-05 1.494 
8 rs590695 70025018 G 0.5727 0.4741 A 6.99E-05 1.492 
11 rs10431058 107481518 A 0.328 0.4258 G 7.03E-05 0.6611 
7 rs534126 142921234 A 0.4911 0.3927 G 7.20E-05 1.491 
11 rs10890742 107474795 G 0.3121 0.4079 A 7.42E-05 0.6573 
17 rs8075721 9956321 G 0.1259 0.2036 A 7.59E-05 0.5696 
1 rs17005517 219604453 A 0.195 0.2828 C 7.72E-05 0.624 
9 rs10868366 88700060 A 0.07092 0.1318 C 7.86E-05 0.4816 
18 rs4401135 69242763 A 0.3865 0.2965 G 7.88E-05 1.518 
3 rs1197312 133125713 C 0.4131 0.5093 A 7.99E-05 0.6663 
16 rs2903692 11238783 A 0.3457 0.4411 G 8.06E-05 0.6631 
11 rs10792493 80297206 G 0.06383 0.1278 A 8.13E-05 0.4784 
6 rs17584185 80381609 G 0.08865 0.153 A 8.17E-05 0.5123 
12 rs12298170 57515363 G 0.3918 0.2993 A 8.31E-05 1.497 
11 rs621942 85783738 A 0.3227 0.2377 C 8.40E-05 1.545 
12 rs17096085 38472919 G 0.0922 0.0457 A 8.46E-05 2.144 
6 rs214544 18284716 A 0.05319 0.1113 G 8.51E-05 0.4442 
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20 rs6074990 15980838 G 0.2651 0.1877 A 8.54E-05 1.618 
22 rs137879 50457041 G 0.3989 0.4954 A 8.56E-05 0.668 
3 rs2114775 16727170 A 0.2961 0.3901 C 8.66E-05 0.6541 
13 rs7330047 76925888 G 0.3777 0.4742 A 8.71E-05 0.6682 
10 rs1000280 100096148 A 0.2961 0.2142 G 8.77E-05 1.562 
2 rs4675790 241859255 A 0.4167 0.3232 C 8.79E-05 1.497 
7 rs17172446 55202598 A 0.2553 0.1781 G 8.85E-05 1.604 
6 rs160699 2776303 G 0.3848 0.4861 A 9.13E-05 0.6832 
11 rs12790863 72979231 G 0.1099 0.1828 A 9.14E-05 0.5555 
2 rs7570320 234075691 A 0.2926 0.3828 C 9.37E-05 0.647 
22 rs5771069 50435480 A 0.3617 0.4576 G 9.57E-05 0.6697 
4 rs2176304 154017805 A 0.3387 0.2523 G 9.85E-05 1.522 
18 rs141913084 14490964 G 0.1093 0.06042 A 9.92E-05 2.054 
Table 5. List of SNPs with a pvalue < 10-5 in the comparison between diabetic individuals and controls. Chromosome positions are reported 
according to GRCh37/hg19 UCSC database. 
 
28 associated polymorphisms are in non-genic regions, while 45 lie in genic loci. Among the 
genic variants, one is in 3’UTR, one downstream region, 35 are intronic and 9 stands in coding 
region, all of them are non-synonymous, suggesting a possible modification in the aminoacidic 
sequence. In this comparison, 5 genes showing more than one associated locus. The MS4A14 
(Membrane Spanning 4-Domains A14) gene shows two associated variants, rs3825020 (p= 4.51E-06) 
and rs4938941 (p= 5.70E-05). The role of the encoding protein is unknown; probably it is part of 
multimeric receptor complex involved in signal transduction. The second gene with two associated 
loci is THSD4 (Thrombospondin Type 1 Domain Containing 4), with rs8032461 (p= 2.38E-05) and 
rs1995334 (p= 3.68E-05). The function of the translated protein is related to peptidase and metallo-
endopeptidase activities. No association with T2D of MS4A14 and THSD4 has been reported. 
Another gene showing more than one associated signal (rs11605196, p= 3.00E-05 and rs11603869, p= 
4.39E-05) is DNHD1 (DND MicroRNA-Mediated Repression Inhibitor 1); protein encodes from this 
gene inhibits microRNA-mediated repression, binding to microRNA-targeting sequences of mRNAs. 
This gene has been associated with several forms of cancer, such as tongue squamous cell and 
embryonal testis carcinomas, but, recently DNHD1 has been identified in mixed ethnicity cases of 
severe proliferative diabetic retinopathy (Ung et al. 2017). Then rs10431058 (p=7.03E-05) and 
rs10890742 (p=7.42E-05) mapped in ELMOD1 (ELMO Domain Containing 1) gene, that encodes for 
a protein with GTPase activator activity and interestingly, mice with mutation in their paralogue 
gene Elmod1, show lower blood glucose levels and lower body weight (de Angelis et al. 2015). 
Finally, three SNPs - rs1729109 (p=3.85E-06), rs1671389 (p=1.92E-05) and rs1671382 (p=6.79E-05) 
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mapped in DLC1 (Deleted in liver cancer 1) gene, another gene whose function is involved in 
GTPase activity regulation, Recently, Shih et al. have demonstrated that the protein encodes by 
DLC1 gene regulates the activity of an inhibitors of matrix metalloproteinases, the plasminogen 
activator inhibitor-1 (PAI-1) (Shih, Takada, and Lo 2012). Noteworthy, there are some evidence that 
PAI-1 is involved in several pathologies such as renal injury, inflammation, obesity and also diabetes 
(Ghosh and Vaughan 2012), suggesting a possibly implication of DLC1 gene in these diseases. 
In the comparison considering diabetic patients and centenarians (figure 3A), 270512 variants 
and 1107 people pass filters and quality controls (QC) check. The first comparison between diabetic 
patients and centenarians showed no significant SNPs with a nominal p-value < 10-8 but we 
identified 38 with p value <10-5 that are listed in Table 6.  
 
CHR SNP BP A1 MAF_A MAF_U A2 P OR 
14 exm1104579 58953746 G 0.2 0.001497 C 5.38E-08 247.8 
18 rs1480923 49480607 A 0.4486 0.3174 G 3.77E-06 1.817 
5 rs2113083 55946967 G 0.4681 0.3503 A 1.54E-05 1.791 
13 rs4307816 87730252 G 0.1578 0.08383 A 1.80E-05 2.265 
4 rs9306973 39627570 A 0.4943 0.3859 G 1.92E-05 1.72 
17 rs1699597 72566351 G 0.5585 0.4521 A 2.18E-05 1.721 
1 exm73271 89524657 C 0.01241 0.0524 G 2.29E-05 0.1535 
6 rs911028 166070424 G 0.2128 0.3039 A 3.12E-05 0.5368 
3 rs874546 127538412 G 0.227 0.1467 A 3.48E-05 2.004 
15 rs12148251 91698922 A 0.2801 0.3802 G 3.55E-05 0.5662 
9 rs891720 116897213 A 0.2642 0.1826 C 4.20E-05 1.853 
6 rs4710283 65506077 A 0.5018 0.3952 G 4.37E-05 1.697 
4 exm2269794 89742764 A 0.3594 0.4641 G 4.85E-05 0.5918 
11 rs573264 114092582 A 0.3954 0.2829 G 4.87E-05 1.717 
2 rs4671379 60495038 A 0.4787 0.3548 G 4.91E-05 1.692 
15 rs11852270 46606919 A 0.2748 0.3817 G 4.94E-05 0.5748 
12 rs634264 118133956 A 0.1738 0.268 G 5.00E-05 0.5316 
4 rs2869950 89742764 A 0.3599 0.4641 G 5.24E-05 0.5936 
3 rs11715363 127515984 G 0.2199 0.1482 A 5.85E-05 1.958 
8 rs6471376 94405276 A 0.3936 0.4985 G 5.88E-05 0.6061 
2 rs2887234 184028531 G 0.3434 0.4476 A 6.43E-05 0.5951 
7 rs414315 154812516 G 0.266 0.3608 A 7.06E-05 0.5761 
6 exm570114 108677977 A 0.06738 0.02844 G 7.25E-05 3.432 
2 rs6716389 176802850 A 0.01434 0.06287 G 7.36E-05 0.1936 
1 rs2067797 234264555 C 0.5391 0.4237 A 7.38E-05 1.669 
6 rs3823036 99284532 G 0.1809 0.2979 A 7.45E-05 0.5649 
6 rs8192591 32185796 A 0.0656 0.02246 G 8.48E-05 3.67 
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10 rs7901695 114754088 G 0.4557 0.3443 A 8.81E-05 1.663 
4 rs7697609 40956574 A 0.2518 0.1662 G 8.83E-05 1.853 
2 rs6750398 236018682 G 0.2057 0.2934 A 9.10E-05 0.5522 
2 rs6714145 174454044 G 0.2535 0.3533 A 9.25E-05 0.585 
16 rs4785345 49807722 A 0.2287 0.1467 G 9.37E-05 1.913 
8 rs590695 70025018 G 0.5727 0.4611 A 9.44E-05 1.635 
2 rs4671386 60514993 C 0.4876 0.3638 A 9.45E-05 1.65 
11 rs752849 47175327 A 0.3191 0.2365 G 9.51E-05 1.749 
4 rs11737809 40895018 A 0.2181 0.1377 G 9.71E-05 1.923 
3 rs1197312 133125713 C 0.4131 0.524 A 9.88E-05 0.6103 
17 rs4968282 44958937 G 0.2447 0.3443 A 9.94E-05 0.5823 
Table 6 . List of SNPs with a pvalue < 10-5 in the comparison between diabetic individuals (N=282) and centenarians (N=334). Chromosome 
positions are reported according to GRCh37/hg19 UCSC database. 
 
In addition, the associated variants were computed using snp-nexus tool (http://snp-
nexus.org/) in order to obtain more informations about genomic mapping, gene/protein consequences 
and effect on protein functions. Within these variants, 14 polymorphisms are non-genic and 24 lie in 
genic region; among these 19 variants are intronic and only 1 in 3’UTR. The last 4 polymorphisms 
lie in codifying regions and are non-synonymous, implying an aminoacid modification in protein 
sequence. Further we focus the analysis on those genes that carry more significant SNPs. In 
particular, we identified two variants -rs7697609 (p=8.83E-05) and rs11737809 (p= 9.71E-05) - located 
in APBB2 gene. The protein encodes by this gene is an amyloid beta precursor binding protein 
(Family B Member 2) which are involved in signal transduction. Two additional significant loci, 
rs874546 (p= 3.48E-05) and rs11715363 (p= 5.85E-05) are located in MGLL gene. The hydrolytic 
protein codifies by this gene is involved in monoacylglycerides and endocannabinoids metabolism. 
The last gene that carries more than one significant loci is FAM13A gene (family with sequence 
similarity 13, member A) with exm2269794 (p=4.85E-05) and rs2869950 (p=5.24E-05). The function of 
the protein codified by this gene is still unknown. While APBB2 and MGLL have never been related 
to T2D trait, the FAM13A gene has been previously associated with fasting insulin (Scott et al. 
2012,) (Yaghootkar et al. 2014). Noteworthy, the rs7901695 (p=8.81E-05) of TCF7L2 gene has 
confirmed its strong association with T2D also in our cohort. 
We recently hypothesized that variants identified in the comparison between centenarians and 
diabetic patients may add a biological validation of the variants identified in the “classical” case-
controls study. Accordingly, we identified those variants that have showed associations in both 
comparisons (diabetic patients VS controls and diabetic patients VS centenarians), considering all the 
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SNPs with p value<10-4 in the two independent comparisons described above. Table 7 reported the 
shared variants. 
 
rs_ID Allele F Diab F Ctrl F Cent P value 
Db/Ctrl 
P value 
Db/Cent 
Gene Chr Position 
rs2056279 G 0.5833 0.4848 0.4566 0.00015 0.000119 ANAPC10 4 145917557 
rs25653 G 0.4096 0.4934 0.5329 0.00076 0.000152 ANPEP 15 90349558 
rs1197312 C 0.4131 0.5093 0.524 8E-05 9.88E-05 BFSP2 3 133125713 
rs17652171 C 0.1613 0.2437 0.2575 3.6E-05 0.000125 CSMD3 8 113662583 
rs170020 G 0.5372 0.4477 0.4401 0.00032 0.000634 CTB_12O2.1 5 151344558 
rs10889061 A 0.3511 0.2715 0.2635 0.0004 0.000718 DAB1 1 58121100 
rs2351921 A 0.511 0.432 0.3952 0.00082 0.000239 DENND5B 12 31667973 
rs12091015 A 0.5195 0.4232 0.4162 6.9E-05 0.000677 DNM3 1 172019718 
rs7854418 G 0.4217 0.3404 0.3338 0.00055 0.00043 DOCK8 9 335545 
rs10829661 A 0.4291 0.3457 0.3383 0.00049 0.000382 EBF3 10 131726740 
rs4710283 A 0.5018 0.4172 0.3952 0.00049 4.37E-05 EYS 6 65506077 
rs17086156 A 0.1223 0.07351 0.06437 0.00045 0.000423 FRMD3 9 85945797 
rs17130717 C 0.01241 0.04702 0.0524 0.00051 2.29E-05 GBP1 1 89524657 
rs45598235 A 0.08511 0.04371 0.04341 0.00028 0.000321 GPR110 6 46977783 
rs4777035 G 0.5071 0.4079 0.3859 6.8E-05 0.00037 ITGA11 15 68605169 
rs4952336 C 0.1489 0.2212 0.2275 0.00028 0.000958 LTBP1 2 33250571 
rs6074990 G 0.2651 0.1877 0.1814 8.5E-05 0.000509 MACROD2 20 15980838 
rs954124 A 0.1578 0.251 0.244 6.5E-06 0.000724 NAA35 9 88563064 
rs8192591 A 0.4947 0.4111 0.4386 0.00065 8.48E-05 NOTCH4 6 32215796 
rs10768450 A 0.2101 0.2907 0.2994 0.00026 0.00058 OR51L1 11 5020832 
rs11734405 G 0.5727 0.4781 0.4491 0.00027 0.000216 OTUD4 4 146081096 
rs3823036 G 0.1809 0.2656 0.2979 6.7E-05 7.45E-05 POU3F2 6 99284532 
rs2272399 A 0.4344 0.3497 0.3428 0.00053 0.000817 SLC6A11 3 10975745 
rs2905964 G 0.3387 0.2556 0.247 0.00019 0.000134 SPOCK1 5 136452856 
rs167769 A 0.3546 0.2616 0.2545 3.5E-05 0.000116 STAT6 12 57503775 
rs7901695 G 0.4557 0.3742 0.3443 0.00079 8.81E-05 TCF7L2 10 114754088 
rs7903146 A 0.4415 0.3623 0.3338 0.00099 0.000122 TCF7L2 10 114758349 
rs2670179 A 0.2943 0.3788 0.3907 0.00034 0.000235 TMEM108 3 133110636 
rs4854583 G 0.4089 0.496 0.506 0.0004 0.000784 TMEM108 3 133112473 
rs3732572 G 0.411 0.4974 0.506 0.00044 0.000897 TMEM108 3 133109469 
rs12461075 A 0.344 0.2636 0.259 0.00033 0.000363 TULP2 19 49399821 
rs6437126 A 0.1348 0.2013 0.2081 0.00037 0.00041 UPP2 2 158865831 
rs1860163 A 0.2855 0.3632 0.3772 0.00085 0.000605 UPP2 2 158870618 
rs160699 G 0.3848 0.4861 0.4701 9.1E-05 0.00032 WRNIP1 6 2776303 
rs4785345 A 0.2287 0.1623 0.1467 0.00051 9.37E-05 ZNF423 16 49807722 
Table 7 . List of SNPs with a pvalue < 10-4 showing association in the two comparisons. Chromosome positions are reported according to 
GRCh37/hg19 UCSC database. 
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Among the 35 shared variants, we found that only one SNP, rs170020, is located in 3’UTR, 
28 SNPs lie in intronic regions and 6 SNPs are placed in coding regions, these latter implying an 
aminoacid substitution in protein sequence (Table 8). 
 
Gene rs_ID P value 
Db/Ctrl 
P value 
Db/Cent 
Gene region Protein Effect Trait (GWAS catalogue) 
ANAPC10 rs2056279 0.00015 0.000119 intronic -- -- 
ANPEP rs25653 0.00076 0.000152 coding nonsyn -- 
BFSP2 rs1197312 8E-05 9.88E-05 intronic -- -- 
CSMD3 rs17652171 3.6E-05 0.000125 intronic -- -- 
CTB_12O2.1 rs170020 0.00032 0.000634 non-coding 
intronic 
-- Interstitial lung disease 
DAB1 rs10889061 0.0004 0.000718 intronic -- -- 
DENND5B rs2351921 0.00082 0.000239 intronic -- -- 
DNM3 rs12091015 6.9E-05 0.000677 intronic -- -- 
DOCK8 rs7854418 0.00055 0.00043 intronic -- -- 
EBF3 rs10829661 0.00049 0.000382 intronic -- -- 
EYS rs4710283 0.00049 4.37E-05 intronic -- -- 
FRMD3 rs17086156 0.00045 0.000423 intronic -- -- 
GBP1 rs17130717 0.00051 2.29E-05 coding nonsyn -- 
GPR110 rs45598235 0.00028 0.000321 coding nonsyn -- 
ITGA11 rs4777035 6.8E-05 0.00037 coding nonsyn -- 
LTBP1 rs4952336 0.00028 0.000958 intronic -- -- 
MACROD2 rs6074990 8.5E-05 0.000509 intronic -- -- 
NAA35 rs954124 6.5E-06 0.000724 intronic -- -- 
NOTCH4 rs8192591 0.00065 8.48E-05 coding nonsyn -- 
OR51L1 rs10768450 0.00026 0.00058 coding nonsyn -- 
OTUD4 rs11734405 0.00027 0.000216 intronic -- -- 
POU3F2 rs3823036 6.7E-05 7.45E-05 3utr -- -- 
SLC6A11 rs2272399 0.00053 0.000817 intronic -- -- 
SPOCK1 rs2905964 0.00019 0.000134 intronic -- -- 
STAT6 rs167769 3.5E-05 0.000116 intronic -- Eosinophilic esophagitis (pediatric) 
TCF7L2 rs7901695 0.00079 8.81E-05 intronic -- Coronary heart disease 
TCF7L2 rs7903146 0.00099 0.000122 intronic -- Type 2 diabetes 
TMEM108 rs2670179 0.00034 0.000235 intronic -- -- 
TMEM108 rs4854583 0.0004 0.000784 intronic -- -- 
TMEM108 rs3732572 0.00044 0.000897 intronic -- -- 
TULP2 rs12461075 0.00033 0.000363 intronic -- -- 
UPP2 rs6437126 0.00037 0.00041 intronic -- -- 
UPP2 rs1860163 0.00085 0.000605 intronic -- -- 
WRNIP1 rs160699 9.1E-05 0.00032 intronic -- -- 
ZNF423 rs4785345 0.00051 9.37E-05 intronic -- -- 
Table 8 List of SNPs with a pvalue < 10-4 showing association in the two comparisons with more than one variant. Gene region, protein 
functions and trait are reported. 
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Also in this comparison we focus on those genes with multiple associated loci. One of them is 
TMEM108 gene, that codes for a transmembrane protein required for the development of neuron 
circuitry and many other functions related to axonal signal transport and neurons connections. Two 
GWASs have identified TMEM108 as possible risk genes for alcohol consumption in European 
populations (Grant et al. 2009) (Heath et al. 2011), and it is also known as a risk locus for psychotic 
disorders (Beveridge and Cairns 2012). Remarkably, several GWAS (Speliotes et al. 2010) 
(Akiyama et al. 2017) and meta-analyses studies (Locke et al. 2015) (Graff et al. 2017)(Justice et al. 
2017) have been reported TMEM18 associated with BMI (Rowlands et al. 2014). UPP2 (Uridine 
Phosphorylase 2) gene is a protein involved in purine metabolism and catalysed the reversible 
phosphorylytic cleavage of uridine and deoxyuridine to uracil and ribose- or deoxyribose-1-
phosphate. Noteworthy, a decrease in expression levels of UPP2 gene have been reported in obese 
mice (Mollah and Ishikawa 2010) and in animal feeding with high fat diet (Eckel-Mahan et al. 2013). 
Interestingly and not surprisingly also transcription factor 7-like 2 (TCF7L2) gene has shown a 
multiple association, with rs7901695 and rs7903146. TCF7L2 gene is a Wnt signalling pathway 
effector, involved in pancreatic beta-cell function, the differentiation of adipocytes and regulation of 
adipokines (Schinner 2009). rs7903146 has been identified as one of the strongest associated variant 
in several studies, among different populations. One copy of the minor allele of rs7903146 (T) 
increased risk for T2D up to 1.37 (Prokopenko, McCarthy, and Lindgren 2008) and carriers of TT 
genotypes show a great increased of TCF7L2 expression in pancreatic islet with impairing insulin 
secretion (Lyssenko et al. 2007). 
In the comparison of diabetic patients and controls, several genes with multiple associated 
variants were identified. In particular, different genes are involved in important cellular mechanism; 
we found in association gene related to transduction signal (MS4A14), to gene expression regulation 
at post-transcriptional levels (DNHD1), involved in metalloprotease activity (THSD4 and DLC1) and 
finally, genes with GTPase activity (ELMOD1 and DLC1). In addition, also in the comparison 
between diabetic patients and centenarians, we found two novel genes that show multiple association 
loci to T2D, APBB2 and MGLL, involved in transduction signal and monoacylglycerides and 
endocannabinoids metabolism, respectively. In addition, we confirmed FAM13A, previously reported 
related to fasting insulin, and TCF7L2 genes as implicated in this form of diabetes. Finally, the 
analysis of shared associated signals, between the “extreme phenotype” approach and the classical 
case control study, confirmed the crucial role played by TCF7L2 and identified two new genes UPP2 
and TMEM108 as potential genetic determinants of type 2 diabetes. While the susceptibility of 
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TCF7L2 have been largely reported, also by our group (Garagnani et al. 2013), very scarce findings 
about the UPP2 and TMEM18 gene in T2D have been reported. It is interesting to underline the 
association of both genes with obesity; in fact it is commonly known that obesity and T2D share 
numerous genetic associated polymorphisms (Zeggini et al. 2008) (Meyre et al. 2009) (Locke et al. 
2015). 
 
Summary: in this study I performed a T2D case control study at genome level in the Italian 
population. T2D patients with at least one complication were compared first with the healthy control 
group and then with centenarians, applying the “extreme phenotypes” approach. In table 9 are 
reported those genes that displayed multiple associated variants in the two comparisons. 
 
Comparison Associated Genes Gene functions 
Diabetics VS Controls DNHD1 
DLC1 
ELMOD1 
M4A14 
TSHD4S 
Gene expression regulation 
GTPase activity 
GTPase activity 
Trasduction signals 
Metallo-protease activity 
Diabetics VS Centenarians APBB2 
FAM13A 
MGLL 
 
TCF7L2 
Trasduction signals 
Unkowmn function 
Monoacylglycerides and 
endocannabinoids metabolisms 
Trascrition factor involved in 
wnt-signal pathway 
Table 9 Genes showing multiple association with p value<10-4 in the two comparisons and their functions. Novel associated genes are in bold. 
 
As summarized in the table, as a whole the present study identified 9 genes with more than 
one associated variant, and 4 of them have never been reported before. Except for FAM13A whose 
function is still unknown, the other genes are involved in crucial cellular processes. Noteworthy, 
some genes are involved in the same functions, i.e. intracellular transduction signals, gene expression 
and GTPase activity regulation. 
Finally, we selected those variants that showed multiple associations and were present in both 
comparisons. The results are reported in table 10. 
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Comparison Shared associated genes Gene functions 
Diabetics VS Controls 
And 
Diabetic VS Centenarians 
TCF7L2 
 
TMEM108 
 
UPP2 
 
Trascrition factor involved in wnt-signal 
pathway 
Transmembrane protein involved in 
neurons activities 
 
Purine metabolism 
Table 10 Genes with multiple association (p value<10-4 ) shared in the two comparisons and their functions. 
Through this analysis 3 genes were identified: TCF7L2, already known as one of the most 
important genes involved in T2D, UPP2, which is likely involved in glucose metabolism, and 
TMEM108, another important risk factor for T2D.  
While confirming the association of some genes with T2D, this study identified novel 
associations with previously unreported loci that might be involved in the most severe forms of 
diabetes. Further investigations to evaluate their role in T2D need to be performed. 
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4.2 Gene-candidate Methylation Analysis 
It is known that only 10-12% of T2D heritability is explained by genetic variability (Ali 
2013), however many environmental factors also have a critical role in the onset of the disease. In 
fact, numerous external influences module gene expression via epigenetic mechanisms; the most 
known and studied is DNA methylation. Studies conduct on models of intrauterine malnutrition and 
intrauterine environmental exposures have reported that epigenetic changes contribute to 
pathogenesis of T2D (Hales and Barker 1992) (Dabelea et al. 2000) (Lee et al. 2005) (Hall et al. 
2014). For this reason, we decided to investigate the role of the methylation status in the onset of 
T2D considering one of the strongest susceptibility locus identified in the previous analysis and by 
recent studies (Mayans et al. 2007) (Sladek et al. 2007) (van Vliet-Ostaptchouk et al. 2007) (Stitzel 
et al. 2010), i.e. TCF7L2 gene. 
Methylation analysis at gene candidate level was performed on 229 diabetic patients and 219 
controls matched for age, sex and BMI. For this analysis we considered three different regions, the 
first located in the promoter region - previously described as differentially methylated in T2D 
patients (Canivell et al. 2014), the other regions investigated were the CpG Islands (CpGIs) 
presented in the entire gene region, one in intron 3 and one in 3’UTR. In Table 11 all informations 
are reported. 
 
 Chromosome Position Gene Region Number of Amplicons Number of CpG Sites 
Promoter Region chr10:114709919-114710801 5’UTR 2 30 
CpG Island 43 chr10:114711916-114712744 Body (Intron 3) 2 54 
Cpg Island 16 chr10:114925323-114925951 3’UTR 1 22 
Table 11 Chromosome positions and CpG Island numbers are reported according to GRCh37 UCSC database.  
 
Firstly we performed the analysis of variance to assess the differences between the two 
groups, we analysed methylations of 84 CpG sites in three regions of TCF7L2. In table 11 are 
listed the means of methylation levels of CpG sites resulted differentially methylated in diabetic 
and controls comparison. 
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As reported, only two CpG sites in intronic CpGI of the TCF7L2 gene showed an association 
signal (CpG_5 p=0.0106; CpG_8.9 p=0.013), while, in the promoter region and in CpGI at 3’UTR 
no CpG associated sites have been identified. Our results do not confirm those of Canivell et al. and 
this might be due to the heterogeneity of the diabetic patients. In their study, in fact, the cohort 
considered including only drug-naive T2D patients, whereas our cohort includes diabetic patients 
diagnosed since several years and pharmacologically treated. Therefore, we can speculate that the 
different results might be due to the heterogeneity of patients considered and to the pharmacological 
treatments that characterized our cohort. 
In the light of how reported by Lyssenko et al., which demonstrated that subjects carriers of 
TT genotypes show a great increased of TCF7L2 expression in pancreatic islet with impairing insulin 
secretion (Lyssenko et al. 2007) we investigated if this connection was due to a methylation 
regulation. Then, we decided to perform an integrated analysis combining genotypes of TCF7L2 
rs7903146 and DNA methylation of the surrounding regions. This is because genetic and epigenetic 
factors may have a combined role in the pathological mechanisms at the basis of the disease. For this 
reason, we decide to evaluate methylation status in the genetic contest of the TCF7L2 gene.  
Then, DNA methylation profiles were grouped based on the genotype of rs7903146 TCF7L2 
of each individual (N=404 including both diabetic patients and controls) and the association between 
the two factors was assessed using the ANalysis Of VAriance (ANOVA), while correcting for sex, 
BMI and age. The analysis was done considering 54 CpG sites. The results are reported in table 12. 
 
 
Gene region CpG sites  Groups Methylation levels ± SD p* (ANOVA) 
Intron 19_CpG_5 T2D 0.6065 ± 0.0796 0.0106 
 Ctrl 0.6265 ± 0.0811  
19_CpG_8.9 T2D 0.1466 ± 0.0747 0.0135 
 Ctrl 0.1678 ± 0.0760  
Table 12 CpG sites showed a significant different methylation levels in T2D individuals and controls are reported. *p values are corrected for 
sex, age and BMI 
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Region CpG Sites Genotypes 
(n) 
Methylation levels ± DS p* 
(ANOVA) 
Pairwase Comparison (p) 
Promoter 3_CpG_12 CC (107) 0.0121 ± 0.0099 0.0027 TT vs TC (0.0355) 
 TC (205) 0.0144 ± 0.0091  TT vs CC (0.0019) 
 TT (92) 0.0179 ± 0.0175   
3_CpG_15 CC (107) 0.1880 ± 0.0626 8.741e-06 CC vs TC (1.5e-05) 
 TC (205) 0.2235 ± 0.0673  CC vs TT (0.00025) 
 TT (92) 0.2235 ± 0.0586   
Intron 13_CpG_28 CC (90) 0.0323 ± 0.0618 0.01615 TT vs TC (0.015) 
 TC (178) 0.0282 ± 0.0870   
 TT (80) 0.0648 ± 0.1414   
19_CpG_1 CC (104) 0.3546 ± 0.1371 0.01298 CC vs TC (0.019) 
 TC (202) 0.4006 ± 0.1393  CC vs TT (0.030) 
 TT (91) 0.4032 ± 0.1385   
Table 13 CpG sites showed a significant different methylation levels in three genotypes groups are reported. *p values are corrected for sex, 
age and BMI 
 
4 CpG sites, 2 in promoter and 2 intronic regions have shown a significant different 
methylation values in three groups. The allele specific methylation values here reported show the 
straight interaction between two risk factors. 
Few studies have attempted to integrate genetic and epigenetic data in the study of T2D so far 
(Bell et al. 2010); Bell et al., have demonstrated a haplotype-specific methylation in the FTO but 
they did not identify any differentially methylated regions (DMRs) in T2D and controls comparison. 
More recently, in one study conducted at epigenome-wide level the authors identified DNA 
methylation variations at level of known GWAS T2D-related loci (Toperoff et al. 2012). In addition, 
an integrated genetic and epigenenetic study in monozygotic twins, has confirmed an enrichment for 
DMR in T2D-susceptibility loci (Yuan et al. 2014). A better understanding of genetic and epigenetic 
interplaying may contribute to improve a disease risk evaluation. 
 
Summary: This is the first DNA methylation study of TCF7L2 where the entire gene region 
has been deeply investigated. We performed a quantitative methylation analysis of 84 CpG sites 
spanning in three regions: the promoter and two CpG Islands in intron 3 and in 3’UTR. We reported 
an association between methylation levels of two CpG sites in intron 3 of TCF7L2 gene with T2D in 
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our population. Moreover, we demonstrated that methylation levels of four CpG sites (two in 
promoter region and two in intron 3) are strongly influenced by the genotype of the most T2D related 
variant, rs7903146. These results showing a high interaction between two important risk factors 
indicate the need for integration of genetic and epigenetic data in order to better understand the basis 
of a complex disease such as T2D. 
4.3 Disease Prediction Models 
At this point it is evident that the search for predisposition to diabetic pathology must take 
into account not only the individual risk factors but also the interaction between them. 
We applied two different approaches in order to develop a disease predictor model able to 
differentiate T2D patients group from the control group. 
Pearson's correlations analysis among all selected variables showed that the variable that has 
the strongest correlation with diabetes is age (figure 4). 
 
Figure 3 Heatmap of Pearsons’ correlation among selected variables. Colours show positive or negative correlation according to the 
scale reported on the right of the figure. 
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In order to develop a disease predictor model able to differentiate T2D individuals from the 
control group, we considered two different approaches. 
Disease Prediction Model 1 
The first approach was based on the computation of a logistic regression model that takes into 
account the following parameters: disease diagnosis, sex, age, BMI, genotypes of rs7903146 and 
methylation levels of the previously investigated TCF7L2 gene (54 CpG sites) in 229 diabetic 
patients and 219 healthy controls. 
In order to investigate the association between each epigenetic and genetic covariate (CpG 
sites and rs7903146) and diabetes, we first performed a 10-fold cross-validated univariate logistic 
regression in which age, sex and BMI were also added as confounding variables. In order to estimate 
the regression coefficients variability and to randomize over the choice, the analysis was repeated 50 
times. Table 13 reports the mean and standard deviation of the coefficients obtained from the 50 
iterations. The first two columns refer to the model coefficient relative to the covariate under 
investigation (row index). Rows were sorted in decreasing order according to the absolute value of 
the covariate-specific regression coefficient (column "Coef mean"), i.e. according to the covariates 
importance. Columns "Age mean", "Age SD", "BMI mean", "BMI SD" and "Sex mean", "Sex SD" 
refer to the mean and standard deviation of the regression coefficients relative to Age, BMI and Sex 
respectively. 
 
 Coef 
mean 
Coef 
SD 
Age 
mean 
Age SD BMI 
mean 
BMI 
SD 
Sex 
mean 
Sex SD Accuracy 
Score 
mean 
Accuracy 
Score SD 
CpG_43_19_CpG_18.19 -0.31154 0.04452 0.85176 0.03977 0.61072 0.03329 0.35106 0.02906 0.66786 0.06637 
CpG_43_19_CpG_13 -0.26459 0.03806 0.83622 0.03561 0.61900 0.03525 0.33167 0.03543 0.66987 0.06586 
CpG_43_19_CpG_5 -0.25858 0.03397 0.82594 0.04605 0.61784 0.03839 0.33127 0.03628 0.68262 0.06514 
CpG_43_19_CpG_8.9 -0.25569 0.03080 0.81301 0.03938 0.59908 0.04146 0.33513 0.03495 0.66880 0.06931 
CpG_43_19_CpG_21.22 -0.24744 0.04516 0.83035 0.03405 0.59678 0.03413 0.35155 0.03158 0.68133 0.06635 
CpG_43_19_CpG_16.17 -0.24484 0.02904 0.83043 0.04234 0.60842 0.04284 0.33287 0.03866 0.66417 0.06677 
CpG_43_19_CpG_1 -0.23991 0.04067 0.82809 0.04158 0.62219 0.03365 0.33480 0.04183 0.67053 0.06645 
CpG_43_13_CpG_5.6 -0.23978 0.04125 0.84970 0.03292 0.60832 0.03729 0.32685 0.03895 0.66987 0.07125 
CpG_43_13_CpG_10 -0.23556 0.03232 0.84838 0.04589 0.60854 0.04201 0.31399 0.03427 0.66978 0.06836 
TCFL2_1_3_CpG_2 0.22138 0.03281 0.81686 0.03998 0.60686 0.04734 0.33997 0.03515 0.67078 0.06230 
TCFL2_1_3_CpG_10 0.22050 0.03180 0.80677 0.04273 0.59743 0.03701 0.33186 0.03663 0.67040 0.06422 
CpG_43_13_CpG_30 0.20596 0.03708 0.83193 0.04022 0.60218 0.04159 0.29620 0.03808 0.67770 0.06502 
CpG_43_19_CpG_23 -0.20169 0.03003 0.81607 0.04186 0.60742 0.02806 0.35236 0.03141 0.67988 0.06154 
CpG_43_13_CpG_11.12 -0.19895 0.03381 0.82987 0.04078 0.60241 0.03808 0.31781 0.02563 0.68765 0.06749 
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CpG_43_19_CpG_11.12 -0.18810 0.02980 0.81927 0.04241 0.60226 0.03698 0.32600 0.02716 0.67765 0.06351 
CpG_43_19_CpG_3.4 -0.18077 0.03054 0.80834 0.04187 0.60568 0.03610 0.33689 0.03330 0.67222 0.06559 
CpG_43_13_CpG_8 -0.17668 0.03052 0.84234 0.04162 0.60043 0.03523 0.32022 0.03837 0.66386 0.06706 
CpG_43_19_CpG_20 -0.17015 0.03268 0.83970 0.03774 0.61375 0.03094 0.34883 0.02932 0.65545 0.06737 
CpG_43_13_CpG_7 -0.16922 0.03469 0.82340 0.03144 0.61012 0.03167 0.31668 0.02992 0.67554 0.06287 
CpG_43_19_CpG_7 -0.15616 0.03389 0.83195 0.04356 0.60539 0.04358 0.33907 0.04103 0.65902 0.06817 
CpG_43_13_CpG_31 -0.14690 0.03139 0.83253 0.03873 0.60358 0.04183 0.32999 0.03957 0.66807 0.06658 
CpG_43_13_CpG_21 -0.14555 0.02944 0.83552 0.04510 0.60331 0.03158 0.33107 0.03494 0.66856 0.06792 
CpG_43_13_CpG_13 0.12611 0.04219 0.82937 0.03432 0.61772 0.03073 0.32764 0.03029 0.67540 0.06804 
CpG_43_13_CpG_22.23 -0.12603 0.04302 0.82489 0.03408 0.59060 0.03946 0.32296 0.03411 0.67021 0.06131 
CpG_43_19_CpG_2 -0.11296 0.04138 0.81233 0.04242 0.60693 0.02615 0.32401 0.03929 0.66248 0.06488 
TCFL2_1_3_CpG_15 0.11002 0.03425 0.82840 0.03601 0.59032 0.03428 0.32364 0.03279 0.66646 0.06847 
CpG_43_13_CpG_9 -0.10988 0.04218 0.83561 0.04585 0.60837 0.04468 0.31667 0.03951 0.66708 0.06850 
7903146_num 0.10653 0.02831 0.82604 0.04518 0.59966 0.03551 0.33278 0.03633 0.66465 0.06781 
CpG_43_19_CpG_6 -0.10473 0.03373 0.83081 0.04195 0.60075 0.03883 0.31151 0.03278 0.66458 0.06997 
TCFL2_1_3_CpG_1 0.10343 0.03424 0.82765 0.04649 0.60495 0.03494 0.31609 0.03153 0.67322 0.06791 
TCFL2_1_3_CpG_9 -0.10021 0.03943 0.82525 0.03717 0.60931 0.03551 0.31384 0.03361 0.65887 0.06337 
CpG_43_13_CpG_28 0.07721 0.04120 0.82623 0.04300 0.59951 0.04006 0.31827 0.03636 0.67354 0.07063 
TCFL2_1_3_CpG_3.4 -0.07619 0.02818 0.83253 0.03961 0.60132 0.03751 0.31550 0.03303 0.66476 0.06752 
TCFL2_1_3_CpG_14 -0.07124 0.03483 0.82644 0.04137 0.61132 0.04058 0.31953 0.03751 0.66800 0.06429 
TCFL2_1_3_CpG_11 -0.07043 0.02980 0.82356 0.04626 0.59808 0.04114 0.31192 0.03500 0.66877 0.06880 
TCFL2_1_3_CpG_12 -0.06850 0.03638 0.82573 0.03803 0.60678 0.04015 0.31797 0.03843 0.66709 0.06640 
CpG_43_13_CpG_2 -0.05141 0.02659 0.82158 0.03851 0.59728 0.03742 0.31433 0.03559 0.66318 0.06471 
CpG_43_13_CpG_17 0.04904 0.03367 0.80994 0.03094 0.60251 0.03730 0.31412 0.03564 0.66796 0.06581 
CpG_43_13_CpG_29 0.02459 0.03123 0.82793 0.03912 0.60780 0.03970 0.31177 0.03409 0.66629 0.06657 
CpG_43_13_CpG_18.19 -0.02002 0.04604 0.82443 0.03501 0.60714 0.03911 0.31779 0.03485 0.66981 0.06502 
CpG_43_13_CpG_4 -0.01899 0.03123 0.82115 0.04480 0.60548 0.04453 0.31835 0.04465 0.66649 0.06779 
TCFL2_1_3_CpG_5 -0.01743 0.03373 0.83462 0.04114 0.61421 0.03402 0.31878 0.03272 0.66652 0.06545 
Table 14 Means and standard deviations (SD) of the coefficients (coef) obtained from the 50 iterations for the first prediction model; mean and 
standard deviation of the regression coefficients relative to age, BMI and sex are also reported. 
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It is worthy of note that age is always the most important covariate in explaining the diabetes 
group, followed by BMI and sex, in agreement with the Pearson's correlation results in Figure 2. 
Finally, the last two columns report the accuracy scores (again, mean and standard deviation of the 
50 repetitions) of each logistic model. As explained in statistical analysis section, the accuracy score 
is equal to the number of samples that are correctly classified by the model divided by the total 
number of samples, i.e. the fraction of samples that are correctly classified. As shown in Table 13, 
the percentage of samples for which the model is able to predict the correct classification ranges 
from 66.7% to 67.0% according to the covariate taken into account. 
The results obtained from the univariate logistic regressions were exploited to select a subset 
of covariates that were subsequently used to train a multivariate model. In particular, we sorted the 
CpG sites according to their univariate average coefficient (absolute value). Then, starting from the 
top of the list, we considered an increasing number of CpG sites to be included in the model and, for 
each subset of CpGs, we performed a double 10-fold cross-validated logistic regression with ridge 
penalization and we estimated the accuracy of the model in predicting T2D. 
Each model also included sex, age, BMI and the genotype of rs7903146 and was re-computed 
50 times to randomize over the cross validation folds choice. Then, for each model, the percentage 
of correctly classified samples over the 50 iterations was computed. Here, a sample was considered 
correctly classified if the model predicts its correct class at least 10% of the times (5 times over 50). 
The results are reported in figure 5. 
 
 
Figure 4 Accuracy score based on number of covariates included 
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As shown, the model with the highest accuracy score turned out to be the one with 5 
covariates, in particular 5 CpG sites in the CpG Island in the intron 3 (CpG43, amp19 CpG sites: 13, 
21.22, 18.19, 5 and 8.9). 
Over the 50 iterations, 63% of samples were correctly classified at least 10% of the times, as 
shown in figure 6. 
 
 
Figure 5 Graphical view of prediction model results. In the figure are reported each sample (x-axis) and the number of each sample are 
wrongly classified (y-axis). 
 
Notice that some samples are always correctly classified, while others are never assigned to 
the right class. This means that the classification is constant but not precise, as the model is able to 
classify correctly only 63% of subjects. 
Finally, we performed a Partial Least Squares (PLS) analysis, that is similar to Principal 
Component Analysis (PCA) but instead of finding the combinations of covariates that maximize the 
variance, it maximizes the covariance with the outcome variable (in our case T2D). Here, we used 
the following covariates: age, sex, BMI, genotype of rs7903146 and the 5 CpG sites that were 
selected according to our method. Results are shown in figure 7. 
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Figure 6 PLS analysis of the results of the first prediction model. On the left graphic subjects are plotted based on two principle 
components, on the right one samples that are wrongly classified in Liner regression model are further identified by red (for 
controls) and blue (for T2D patients) colour. 
The figure on the left shows the patients (points) plotted in the space defined by the first 2 
PLS components. As it can be appreciated, the two groups are largely overlapping. If we identify 
with darker colours (red for healthy controls, blue for T2D patients) the samples that were wrongly 
classified by the Logistic regression model, we see that PLS confirms the result: healthy controls that 
were wrongly classified by the logistic model overlap with T2D patients and vice versa. 
Disease Prediction Model 2 
The second approach that we applied was based on the development of a predictive model for 
the biological age of an individual based on DNA methylation measurements. 
At variance with the first model, the regions that have been selected resulted to be associated 
with biological age in previous studies. In particular, we took into account at least 4 sets of CpG sites 
whose level of methylation is age-dependent: a) the CpG sites included in Horvath’s clock (Horvath 
2013); b) the CpG sites included in Hannum’s clock (Hannum et al. 2013); c) the CpG sites included 
in a recent meta-analysis that we performed to identify age-associated DNA methylation changes in 
blood (Bacalini et al. 2015); d) the CpG sites which show an increase in inter-individual variability 
in DNA methylation with age, according to a recent study (Slieker et al. 2016). According to the 
correlation with chronological age and to the association with age-related conditions results obtained 
from this investigation, three target loci have been chosen: ELOVL2, CA3 and LYPD5. We 
performed a design specific EpiTYPER assays onto the surrounding CpG sites not assessed by the 
Infinium platform, in order to evaluate the DNA methylation status of the above identified genes that 
allows investigation of 16 CpG sites on promoter region of ELOVL2 gene, 6 CpG sites on the 
promoter region of CA3 gene and 10 on the 3’ untranslated region of LYPD5 gene. 
This analysis was performed on 298 healthy controls from 0 to 100 years, 24 centenarians, 24 
centenarians’ offspring, 16 subjects with Down Syndrome and 181 T2D patients. DNA methylation 
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levels of 32 CpG sites were assessed using EpiTYPER technology (Agena Bio, San Diego, CA, 
USA). The regions have been selected as described in experimental procedures. 
Epigenetic Age (EpiAge) was estimated performing a Linear Regression on the control group 
based on the 32 selected CpGs. EpiAge of the remaining groups was predicted using the coefficients 
of the model trained on controls. Results are shown in figure 8. 
 
Figure 7 Scatter plot of the EpiAge of subjects as a function of their Real Age. Colours refer to different groups according to the figure legend. 
The dashed line corresponds to the bisector (EpiAge = Real Age). The blue line represent the regression line obtaine d for the healthy control 
group and the shadow around it indicates the 95% confidence interval. 
 
The slope and r2 value for each analysed group are reported in table 14. 
 
Group Slope value r2 value 
Control 0.68 0.83 
Centenarians 1.73 0.41 
Centenarians’ Offspring 0.86 0.29 
Cord blood na 0.0 
Down Syndrome 1.01 0.78 
T2D 0.54 0.35 
Table 15 Slope and r2 values resulted from linear regression model are reported for each sample group considered. 
 
As reported in the scatter plot, the healthy control group spreads around the central line 
showing a high correlation between chronological age (real age) and epigenetic predicted age 
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(EpiAge). The centenarians group and the majority of their offspring showed a deceleration of their 
EpiAge. In contrast, subjects with Down Syndrome have shown an acceleration of EpiAge. Quite 
surprisingly, the group of T2D patients did not display an acceleration of EpiAge, on the contrary 
some T2D patients showed a deceleration of EpiAge. 
Summary: The first prediction model based on linear regression analysis was developed 
using one of the strongest diabetes related variant (rs7903146 of TCF7L2 gene), phenotypic trait 
(BMI, sex, age) and methylation levels of 5 CpG sites in intron 3 region of TCF7L2 gene. Although 
63% of samples were correctly classified as healthy controls or T2D patients, the accuracy of our 
model is not satisfactory and needs to be improved. As reported in PLS analysis, in fact, the two 
groups are largely overlapped. These results suggesting that other variables (phenotypic trait, 
biochemistry parameters and clinical informations) are requested in order to improve the accuracy of 
the model. Another important aspect with likely impact in the model prediction performance is the 
high phenotypic heterogeneity involved in T2D. To this regard, Wen and Liu demonstrated that the 
use of more refined subphenotypes facilitates the identification of new predictors and leads to 
improved risk prediction models (Wen and Lu 2013). 
The second prediction model was based on the estimation of age derived from epigenetic 
levels of particular CpG sites on the genome. Taking a lesson from Epigenetic Clock of Horvath’s, 
the most popular epigenetic age (EpiAge) estimator reported so far (Horvath 2013), we developed a 
“epigenetic little clock” based on methylation values of only 32 CpG sites belonging to three genes 
(ELOVL2, CA3 and LYPD5). As many studies have been reported a modification of EpiAge in 
presence of age-related diseases, cancer or Down Syndrome (Levine et al. 2015) (Horvath and Ritz 
2015) we decided to evaluate epigenetic clock modification in our T2D samples. Here we applied 
our “epigenetic little clock” for biological age estimation in diabetes patients, in order to evaluate a 
possible acceleration of epigenetic age in T2D patients due to the disease. Surprisingly, T2D patients 
did not show an acceleration of epigenetic age, conversely, some of them seem to have a deceleration 
of EpiAge. A possible explanation for these results might be the interaction with environmental 
factors or pharmaceutical therapies that might affect the methylation status. 
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5 Conclusions 
Unravelling the etiopathology of Type 2 diabetes (T2D) is a major challenge due to the 
extreme heterogeneity of the disease. Actually, T2D is a common complex and multifactorial disease 
caused by the interaction of genetics, epigenetics and environmental factors; studies that evaluate the 
combined effect of these factors represent a novel field of research for this complex disorder. 
In the present thesis we present an integrated genetic and epigenetic analysis of a cohort of 
Italian subjects. First, we performed a GWAS of 1352 individuals (cases=282 and controls=1070), 
following the approach of the “extreme phenotypes” that we recently suggested in the study of age-
related diseases, in order to increase sensitivity and to identify the variants with a possible biological 
function. In the first comparison between 282 T2D patients with at least one vascular complication 
and 737 healthy controls we found 73 associated variants with nominal p values <10-5 in the logistic 
regression analysis. Then, we focus on those genes that carry at least two significant SNPs (p<10-4); 
by this analysis we identified 5 genes with multiple associated signals: MS4A14 and THSD4 genes, 
involved in transduction signal and post transcriptional gene expression, respectively, that had never 
been associated to T2D. Conversely, DNHD1 gene, that regulates gene expression by binding to 
mRNA at level of microRNA target sequences, has been related of severe proliferative diabetic 
retinopathy (Ung, 2017). Finally, two genes that encode for GTPase activity proteins have been 
found in association with multiple signals in our study: ELMOD1 gene, previously associated with 
low blood glucose levels and low body weight in mice (de Angelis et al. 2015) and DLC1 gene, 
recently identifies as a modulator of the plasminogen activator inhibitor-1 (PAI-1) involved in 
several pathologies such as renal injury, inflammation, obesity and also diabetes (Shih, Takada, and 
Lo 2012). 
When we considered 282 T2D patients with at least one vascular complication with 334 
centenarians, we found 38 associated variants with nominal p value <10-5. Moreover, we selected 
those genes with more than one associated SNP with p<10-4,. We identified two novel signals, 
APBB2 gene, that encodes for a protein involved in transduction signal, and MGLL, which 
participates in monoacylglycerides and endocannabinoids metabolism. Moreover, we identified two 
genes previously reported associated with the disease: FAM13A, found in association with fasting 
insulin in two studies (Scott et al. 2012;) (Yaghootkar et al. 2014) and TCF7L2, the strongest locus 
related to T2D to date and previously described by our group (Garagnani et al. 2013). 
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Then, we identified the number of associated variants that were present in the two 
comparisons described above (T2D vs ctrl and T2D vs centenarians). This analysis revealed a total of 
35 common variants that we hypothesized to be the variants with a high biological value. 
As illustrated above, we focused on variants showing multiple associations among those 
having p value <10-4. Then we identified three genes shared between the two comparisons: 
TMEM108, that codes for a transmembrane protein involved in neuronal activities, UPP2 gene, 
involved in purine metabolism and once again TCF7L2 gene. Numerous evidences have been 
reported for TMEM108 gene as related with BMI (Locke et al. 2015) (Graff et al. 2017) (Justice et al. 
2017) (Rowlands et al. 2014); obese mice (Mollah and Ishikawa 2010) and animal fed with high fat 
diet (Eckel-Mahan et al. 2013) have showed a decrease in the expression levels of UPP2 gene. 
Finally, TCF7L2 gene was confirmed as one of the most important predictors for T2D genetic risk. 
In conclusion the analysis of extreme phenotypes allows us to describe significant associations even 
if the number of our samples is not very high. This suggests that the cohorts identified and the use of 
centenarians as group of “supercontrols” maximize the differences observed from a biological point 
of view. 
Since TCF7L2 is considered the master gene for T2D, we conducted a gene-candidate 
methylation analysis of this gene, (Mayans et al. 2007 Sladek et al. 2007; van Vliet-Ostaptchouk et 
al. 2007; Stitzel et al. 2010). The analysis was performed considering 229 T2D patients and 219 age 
and sex matched controls, on the promoter region, previously associated with T2D in a Spanish 
population (Canivell et al. 2014), as well as in two CpG Islands (CpGI) in intron 3 and in 3’ UTR of 
TCF7L2 gene. The analysis of variance (ANOVA) performed on 70 CpG sites has shown two CpG 
sites in intronic CpGI having different methylation values between T2D patients and healthy 
controls. Subsequently, we performed an integrated analysis combining genotypes of TCF7L2 
rs7903146 and DNA methylation of the surrounding regions. The ANOVA analysis conducted on 
404 samples grouped based on the genotypes of rs7903146 has shown a different methylation level 
in three groups. In conclusion we suggested that a DNA methylation variability exists that separates 
T2D patients from controls, and that TCF7L2 rs7903146 influences methylation profile of the gene 
independently from phenotype. 
Finally, we developed and tested two different disease predictor models considering some of 
these genetic and epigenetic variables, in order to check the possibility to differentiate T2D patients 
group from the controls group, and eventually to identify persons at risk of developing T2D before 
the onset of the disease.  
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The first method was based on the computation of a logistic regression model on the 
following parameters: disease diagnosis, sex, age, BMI, genotypes of rs7903146 and methylation 
levels of 5 CpG sites in TCF7L2 gene in 229 diabetic subjects and 219 controls. 
This model was able to correctly classify 63% of subjects, resulting mildly accurate and for 
this reason it will be integrated with more parameters in order to improve its accuracy. 
The second approach was based on a predictive model for the biological age of an individual 
based on DNA methylation measurements. We developed a “epigenetic little clock” trough the 
methylation status of 32 CpG sites of three genes (ELOVL2, CA3 and LYPD5). The analysis was 
performed on 298 healthy subjects (age range=0-99 years), 24 centenarians, 24 centenarians’ 
offspring, 16 subjects with Down Syndrome and 181 T2D patients. The centenarians group and the 
majority of their offspring showed a deceleration of their epigenetic age, conversely, subjects with 
Down Syndrome showed an acceleration of epigenetic age. Unexpectedly, this analysis has shown 
that diabetic patients did not show an acceleration of epigenetic age. These results might be 
influenced by environmental factors, such as physical activity or diet, or drugs therapies that might 
modify methylation status. Recently evidence shown that metformin, one of the most used anti-
diabetic drug, have an anti-aging effect (Pryor and Cabreiro 2015; Podhorecka, Ibanez, and 
Dmoszyńska 2017). 
In conclusion, in here described GWAS analysis, including 1389 Italians individuals, we 
identified several loci previously described in association with T2D and some novel genes possibly 
involved in the disease identified thanks to the extreme phenotype approach. Remarkably, the 
“extreme phenotypes” approach gives more value of our study and it could be a valid tool in the 
study of complex age-related disease allowing the identification of variants with biological 
significance. The gene candidate methylation study indicates an association of methylation for 
TCF7L2 gene and T2D and moreover it demonstrates a straight interaction between genotypes and 
methylation, underling the need to perform more comprehensive studies for better improving a 
disease risk evaluation. Linear regression model for prediction of the disease has shown a weak 
accuracy and it will be implemented with other parameters. Finally, T2D patients did not show an 
acceleration of epigenetic age in our samples, further investigations are needed in order to evaluate 
how the environment, drugs or lifestyle can influence them. 
  
37 
 
 
6 Bibliography 
 
 
Abbott, Alison 
 2004 Ageing: Growing Old Gracefully. Nature 428(6979): 116–118. 
 
Achilli, Alessandro, Anna Olivieri, Maria Pala, et al. 
 2011 Mitochondrial DNA Backgrounds Might Modulate Diabetes Complications Rather than 
T2DM as a Whole. PloS One 6(6): e21029. 
 
Akiyama, Masato, Yukinori Okada, Masahiro Kanai, et al. 
 2017 Genome-Wide Association Study Identifies 112 New Loci for Body Mass Index in the 
Japanese Population. Nature Genetics 49(10): 1458–1467. 
 
Ali, Omar 
 2013 Genetics of Type 2 Diabetes. World Journal of Diabetes 4(4): 114–123. 
 
Anderson, Carl A., Fredrik H Pettersson, Geraldine M Clarke, et al. 
 2010 Data Quality Control in Genetic Case-Control Association Studies. Nature Protocols 5(9): 
1564–1573. 
 
de Angelis, Martin Hrabě, George Nicholson, Mohammed Selloum, et al. 
 2015 Analysis of Mammalian Gene Function through Broad-Based Phenotypic Screens across a 
Consortium of Mouse Clinics. Nature Genetics 47(9): 969–978. 
 
Bacalini, Maria Giulia, Alessio Boattini, Davide Gentilini, et al. 
 2015 A Meta-Analysis on Age-Associated Changes in Blood DNA Methylation: Results from an 
Original Analysis Pipeline for Infinium 450k Data. Aging 7(2): 97–109. 
 
Bell, Christopher G., Sarah Finer, Cecilia M. Lindgren, et al. 
 2010 Integrated Genetic and Epigenetic Analysis Identifies Haplotype-Specific Methylation in the 
FTO Type 2 Diabetes and Obesity Susceptibility Locus. PloS One 5(11): e14040. 
 
Beveridge, Natalie J., and Murray J. Cairns 
 2012 MicroRNA Dysregulation in Schizophrenia. Neurobiology of Disease 46(2): 263–271. 
 
Bonafè, Massimiliano, and Fabiola Olivieri 
 2009 Genetic Polymorphism in Long-Lived People: Cues for the Presence of an Insulin/IGF-
38 
 
Pathway-Dependent Network Affecting Human Longevity. Molecular and Cellular Endocrinology 
299(1): 118–123. 
 
Candore, Giuseppina, Carmela R. Balistreri, Florinda Listì, et al. 
 2006 Immunogenetics, Gender, and Longevity. Annals of the New York Academy of Sciences 
1089: 516–537. 
 
Candore, Giuseppina, Calogero Caruso, and Giuseppina Colonna-Romano 
 2010 Inflammation, Genetic Background and Longevity. Biogerontology 11(5): 565–573. 
 
Canivell, Silvia, Elena G. Ruano, Antoni Sisó-Almirall, et al. 
 2014 Differential Methylation of TCF7L2 Promoter in Peripheral Blood DNA in Newly 
Diagnosed, Drug-Naïve Patients with Type 2 Diabetes. PLoS ONE 9(6). 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051650/, accessed November 21, 2017. 
 
Carrieri, G., M. Bonafè, M. De Luca, et al. 
 2001 Mitochondrial DNA Haplogroups and APOE4 Allele Are Non-Independent Variables in 
Sporadic Alzheimer’s Disease. Human Genetics 108(3): 194–198. 
 
Cevenini, E., L. Invidia, F. Lescai, et al. 
 2008 Human Models of Aging and Longevity. Expert Opinion on Biological Therapy 8(9): 1393–
1405. 
 
Chambers, John C., Marie Loh, Benjamin Lehne, et al. 
 2015 Epigenome-Wide Association of DNA Methylation Markers in Peripheral Blood from Indian 
Asians and Europeans with Incident Type 2 Diabetes: A Nested Case-Control Study. The Lancet. 
Diabetes & Endocrinology 3(7): 526–534. 
 
Dabelea, D., R. L. Hanson, R. S. Lindsay, et al. 
 2000 Intrauterine Exposure to Diabetes Conveys Risks for Type 2 Diabetes and Obesity: A Study 
of Discordant Sibships. Diabetes 49(12): 2208–2211. 
 
Danaei, Goodarz, Mariel M. Finucane, Yuan Lu, et al. 
 2011 National, Regional, and Global Trends in Fasting Plasma Glucose and Diabetes Prevalence 
since 1980: Systematic Analysis of Health Examination Surveys and Epidemiological Studies with 
370 Country-Years and 2·7 Million Participants. Lancet (London, England) 378(9785): 31–40. 
 
Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis 
Institutes of BioMedical Research, Richa Saxena, Benjamin F. Voight, et al. 
 2007 Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride 
Levels. Science (New York, N.Y.) 316(5829): 1331–1336. 
 
Duggirala, R., J. Blangero, L. Almasy, et al. 
39 
 
 1999 Linkage of Type 2 Diabetes Mellitus and of Age at Onset to a Genetic Location on 
Chromosome 10q in Mexican Americans. American Journal of Human Genetics 64(4): 1127–1140. 
 
Eckel-Mahan, Kristin L., Vishal R. Patel, Sara de Mateo, et al. 
 2013 Reprogramming of the Circadian Clock by Nutritional Challenge. Cell 155(7): 1464–1478. 
 
Florath, Ines, Katja Butterbach, Jonathan Heiss, et al. 
 2016 Type 2 Diabetes and Leucocyte DNA Methylation: An Epigenome-Wide Association Study 
in over 1,500 Older Adults. Diabetologia 59(1): 130–138. 
 
Fontana, Luigi, and Samuel Klein 
 2007 Aging, Adiposity, and Calorie Restriction. JAMA 297(9): 986–994. 
 
Franceschi, C., and M. Bonafè 
 2003 Centenarians as a Model for Healthy Aging. Biochemical Society Transactions 31(2): 457–
461. 
 
Franceschi, C., L. Motta, S. Valensin, et al. 
 2000 Do Men and Women Follow Different Trajectories to Reach Extreme Longevity? Italian 
Multicenter Study on Centenarians (IMUSCE). Aging (Milan, Italy) 12(2): 77–84. 
 
Franceschi, Claudio, Luciano Motta, Massimo Motta, et al. 
 2008 The Extreme Longevity: The State of the Art in Italy. Experimental Gerontology 43(2): 45–
52. 
 
Franceschi, Claudio, Fabiola Olivieri, Francesca Marchegiani, et al. 
 2005 Genes Involved in Immune Response/Inflammation, IGF1/Insulin Pathway and Response to 
Oxidative Stress Play a Major Role in the Genetics of Human Longevity: The Lesson of 
Centenarians. Mechanisms of Ageing and Development 126(2): 351–361. 
 
Garagnani, Paolo, Cristina Giuliani, Chiara Pirazzini, et al. 
 2013 Centenarians as Super-Controls to Assess the Biological Relevance of Genetic Risk Factors 
for Common Age-Related Diseases: A Proof of Principle on Type 2 Diabetes. Aging 5(5): 373–385. 
 
Gaulton, Kyle J., Cristen J. Willer, Yun Li, et al. 
 2008 Comprehensive Association Study of Type 2 Diabetes and Related Quantitative Traits with 
222 Candidate Genes. Diabetes 57(11): 3136–3144. 
 
Ghosh, Asish K., and Douglas E. Vaughan 
 2012 PAI-1 in Tissue Fibrosis. Journal of Cellular Physiology 227(2): 493–507. 
 
Giuliani, Cristina, Chiara Pirazzini, Massimo Delledonne, et al. 
40 
 
 2017 Centenarians as Extreme Phenotypes: An Ecological Perspective to Get Insight into the 
Relationship between the Genetics of Longevity and Age-Associated Diseases. Mechanisms of 
Ageing and Development 165(Pt B): 195–201. 
 
Graff, Mariaelisa, Robert A. Scott, Anne E. Justice, et al. 
 2017 Genome-Wide Physical Activity Interactions in Adiposity - A Meta-Analysis of 200,452 
Adults. PLoS Genetics 13(4): e1006528. 
 
Grant, Julia D., Arpana Agrawal, Kathleen K. Bucholz, et al. 
 2009 Alcohol Consumption Indices of Genetic Risk for Alcohol Dependence. Biological 
Psychiatry 66(8): 795–800. 
 
Hales, C. N., and D. J. Barker 
 1992 Type 2 (Non-Insulin-Dependent) Diabetes Mellitus: The Thrifty Phenotype Hypothesis. 
Diabetologia 35(7): 595–601. 
 
Hall, Elin, Petr Volkov, Tasnim Dayeh, et al. 
 2014 Effects of Palmitate on Genome-Wide MRNA Expression and DNA Methylation Patterns in 
Human Pancreatic Islets. BMC Medicine 12: 103. 
 
Hanis, C. L., E. Boerwinkle, R. Chakraborty, et al. 
 1996 A Genome-Wide Search for Human Non-Insulin-Dependent (Type 2) Diabetes Genes 
Reveals a Major Susceptibility Locus on Chromosome 2. Nature Genetics 13(2): 161–166. 
 
Hannum, Gregory, Justin Guinney, Ling Zhao, et al. 
 2013 Genome-Wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates. 
Molecular Cell 49(2): 359–367. 
 
Heath, Andrew C., John B. Whitfield, Nicholas G. Martin, et al. 
 2011 A Quantitative-Trait Genome-Wide Association Study of Alcoholism Risk in the 
Community: Findings and Implications. Biological Psychiatry 70(6): 513–518. 
 
Herskind, A. M., M. McGue, N. V. Holm, et al. 
 1996 The Heritability of Human Longevity: A Population-Based Study of 2872 Danish Twin Pairs 
Born 1870-1900. Human Genetics 97(3): 319–323. 
 
vB Hjelmborg, Jacob, Ivan Iachine, Axel Skytthe, et al. 
 2006 Genetic Influence on Human Lifespan and Longevity. Human Genetics 119(3): 312–321. 
 
Horvath, Steve 
 2013 DNA Methylation Age of Human Tissues and Cell Types. Genome Biology 14(10): R115. 
41 
 
 
Horvath, Steve, and Beate R. Ritz 
 2015 Increased Epigenetic Age and Granulocyte Counts in the Blood of Parkinson’s Disease 
Patients. Aging 7(12): 1130–1142. 
 
Jin, Tianru, and Ling Liu 
 2008 The Wnt Signaling Pathway Effector TCF7L2 and Type 2 Diabetes Mellitus. Molecular 
Endocrinology (Baltimore, Md.) 22(11): 2383–2392. 
 
Justice, Anne E., Thomas W. Winkler, Mary F. Feitosa, et al. 
 2017 Genome-Wide Meta-Analysis of 241,258 Adults Accounting for Smoking Behaviour 
Identifies Novel Loci for Obesity Traits. Nature Communications 8: 14977. 
 
Kulkarni, Hemant, Mark Z. Kos, Jennifer Neary, et al. 
 2015 Novel Epigenetic Determinants of Type 2 Diabetes in Mexican-American Families. Human 
Molecular Genetics 24(18): 5330–5344. 
 
Lee, Yun Yong, Kyong Soo Park, Youngmi Kim Pak, and Hong Kyu Lee 
 2005 The Role of Mitochondrial DNA in the Development of Type 2 Diabetes Caused by Fetal 
Malnutrition. The Journal of Nutritional Biochemistry 16(4): 195–204. 
 
Levine, Morgan E., Ake T. Lu, David A. Bennett, and Steve Horvath 
 2015 Epigenetic Age of the Pre-Frontal Cortex Is Associated with Neuritic Plaques, Amyloid Load, 
and Alzheimer’s Disease Related Cognitive Functioning. Aging 7(12): 1198–1211. 
 
Liu, Jun, Sabina Semiz, Sven J. van der Lee, et al. 
 2017 Metabolomics Based Markers Predict Type 2 Diabetes in a 14-Year Follow-up Study. 
Metabolomics: Official Journal of the Metabolomic Society 13(9): 104. 
 
Locke, Adam E., Bratati Kahali, Sonja I. Berndt, et al. 
 2015 Genetic Studies of Body Mass Index Yield New Insights for Obesity Biology. Nature 
518(7538): 197–206. 
 
Lyssenko, Valeriya, Roberto Lupi, Piero Marchetti, et al. 
 2007 Mechanisms by Which Common Variants in the TCF7L2 Gene Increase Risk of Type 2 
Diabetes. Journal of Clinical Investigation 117(8): 2155–2163. 
 
Mayans, Sofia, Kurt Lackovic, Petter Lindgren, et al. 
 2007 TCF7L2 Polymorphisms Are Associated with Type 2 Diabetes in Northern Sweden. 
European Journal of Human Genetics: EJHG 15(3): 342–346. 
 
Meyre, David, Jérôme Delplanque, Jean-Claude Chèvre, et al. 
42 
 
 2009 Genome-Wide Association Study for Early-Onset and Morbid Adult Obesity Identifies Three 
New Risk Loci in European Populations. Nature Genetics 41(2): 157–159. 
 
Mollah, Md Bazlur R, and Akira Ishikawa 
 2010 A Wild Derived Quantitative Trait Locus on Mouse Chromosome 2 Prevents Obesity. BMC 
Genetics 11: 84. 
 
Pal, A., and M. I. McCarthy 
 2013 The Genetics of Type 2 Diabetes and Its Clinical Relevance. Clinical Genetics 83(4): 297–
306. 
 
Paolisso, G., A. Gambardella, S. Ammendola, et al. 
 1996 Glucose Tolerance and Insulin Action in Healty Centenarians. The American Journal of 
Physiology 270(5 Pt 1): E890-894. 
 
Podhorecka, Monika, Blanca Ibanez, and Anna Dmoszyńska 
 2017 Metformin - Its Potential Anti-Cancer and Anti-Aging Effects. Postepy Higieny I Medycyny 
Doswiadczalnej (Online) 71(0): 170–175. 
 
Prokopenko, Inga, Mark I. McCarthy, and Cecilia M. Lindgren 
 2008 Type 2 Diabetes: New Genes, New Understanding. Trends in Genetics: TIG 24(12): 613–
621. 
 
Pryor, Rosina, and Filipe Cabreiro 
 2015 Repurposing Metformin: An Old Drug with New Tricks in Its Binding Pockets. The 
Biochemical Journal 471(3): 307–322. 
 
Roth, George S., Julie A. Mattison, Mary Ann Ottinger, et al. 
 2004 Aging in Rhesus Monkeys: Relevance to Human Health Interventions. Science (New York, 
N.Y.) 305(5689): 1423–1426. 
 
Rowlands, David S., Rachel A. Page, William R. Sukala, et al. 
 2014 Multi-Omic Integrated Networks Connect DNA Methylation and MiRNA with Skeletal 
Muscle Plasticity to Chronic Exercise in Type 2 Diabetic Obesity. Physiological Genomics 46(20): 
747–765. 
 
Salvioli, S., F. Olivieri, F. Marchegiani, et al. 
 2006 Genes, Ageing and Longevity in Humans: Problems, Advantages and Perspectives. Free 
Radical Research 40(12): 1303–1323. 
 
Schinner, S. 
 2009 Wnt-Signalling and the Metabolic Syndrome. Hormone and Metabolic Research = Hormon- 
Und Stoffwechselforschung = Hormones Et Metabolisme 41(2): 159–163. 
43 
 
 
Scott, Laura J., Karen L. Mohlke, Lori L. Bonnycastle, et al. 
 2007 A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple 
Susceptibility Variants. Science (New York, N.Y.) 316(5829): 1341–1345. 
 
Scott, Robert A., Vasiliki Lagou, Ryan P. Welch, et al. 
 2012 Large-Scale Association Analyses Identify New Loci Influencing Glycemic Traits and 
Provide Insight into the Underlying Biological Pathways. Nature Genetics 44(9): 991–1005. 
 
Seki, Yoshinori, Lyda Williams, Patricia M. Vuguin, and Maureen J. Charron 
 2012 Minireview: Epigenetic Programming of Diabetes and Obesity: Animal Models. 
Endocrinology 153(3): 1031–1038. 
 
Shah, Viral N., Balneek Singh Cheema, Rajni Sharma, et al. 
 2013 ACACβ Gene (Rs2268388) and AGTR1 Gene (Rs5186) Polymorphism and the Risk of 
Nephropathy in Asian Indian Patients with Type 2 Diabetes. Molecular and Cellular Biochemistry 
372(1–2): 191–198. 
 
Shigemizu, Daichi, Testuo Abe, Takashi Morizono, et al. 
 2014 The Construction of Risk Prediction Models Using GWAS Data and Its Application to a 
Type 2 Diabetes Prospective Cohort. PloS One 9(3): e92549. 
 
Shih, Yi-Ping, Yoshikazu Takada, and Su Hao Lo 
 2012 Silencing of DLC1 Upregulates PAI-1 Expression and Reduces Migration in Normal Prostate 
Cells. Molecular Cancer Research: MCR 10(1): 34–39. 
 
Skinner, Michael K. 
 2011 Environmental Epigenetic Transgenerational Inheritance and Somatic Epigenetic Mitotic 
Stability. Epigenetics 6(7): 838–842. 
 
Sladek, Robert, Ghislain Rocheleau, Johan Rung, et al. 
 2007 A Genome-Wide Association Study Identifies Novel Risk Loci for Type 2 Diabetes. Nature 
445(7130): 881–885. 
 
Slieker, Roderick C., Maarten van Iterson, René Luijk, et al. 
 2016 Age-Related Accrual of Methylomic Variability Is Linked to Fundamental Ageing 
Mechanisms. Genome Biology 17(1): 191. 
 
Speliotes, Elizabeth K., Cristen J. Willer, Sonja I. Berndt, et al. 
 2010 Association Analyses of 249,796 Individuals Reveal 18 New Loci Associated with Body 
Mass Index. Nature Genetics 42(11): 937–948. 
44 
 
 
Stern, M. P., P. A. Morales, R. A. Valdez, et al. 
 1993 Predicting Diabetes. Moving beyond Impaired Glucose Tolerance. Diabetes 42(5): 706–714. 
 
Stitzel, Michael L., Praveen Sethupathy, Daniel S. Pearson, et al. 
 2010 Global Epigenomic Analysis of Primary Human Pancreatic Islets Provides Insights into Type 
2 Diabetes Susceptibility Loci. Cell Metabolism 12(5): 443–455. 
 
Toperoff, Gidon, Dvir Aran, Jeremy D. Kark, et al. 
 2012 Genome-Wide Survey Reveals Predisposing Diabetes Type 2-Related DNA Methylation 
Variations in Human Peripheral Blood. Human Molecular Genetics 21(2): 371–383. 
 
Ung, Cindy, Angie V. Sanchez, Lishuang Shen, et al. 
 2017 Whole Exome Sequencing Identification of Novel Candidate Genes in Patients with 
Proliferative Diabetic Retinopathy. Vision Research. 
 
Vaiserman, Alexander M. 
 2017 Early-Life Nutritional Programming of Type 2 Diabetes: Experimental and Quasi-
Experimental Evidence. Nutrients 9(3). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372899/, 
accessed December 5, 2017. 
 
van Vliet-Ostaptchouk, J. V., R. Shiri-Sverdlov, A. Zhernakova, et al. 
 2007 Association of Variants of Transcription Factor 7-like 2 (TCF7L2) with Susceptibility to 
Type 2 Diabetes in the Dutch Breda Cohort. Diabetologia 50(1): 59–62. 
 
Voight, Benjamin F., Laura J. Scott, Valgerdur Steinthorsdottir, et al. 
 2010 Twelve Type 2 Diabetes Susceptibility Loci Identified through Large-Scale Association 
Analysis. Nature Genetics 42(7): 579–589. 
 
Wen, Yalu, and Qing Lu 
 2013 A Multiclass Likelihood Ratio Approach for Genetic Risk Prediction Allowing for 
Phenotypic Heterogeneity. Genetic Epidemiology 37(7): 715–725. 
 
Yaghootkar, Hanieh, Robert A. Scott, Charles C. White, et al. 
 2014 Genetic Evidence for a Normal-Weight “Metabolically Obese” Phenotype Linking Insulin 
Resistance, Hypertension, Coronary Artery Disease, and Type 2 Diabetes. Diabetes 63(12): 4369–
4377. 
 
Yuan, Wei, Yudong Xia, Christopher G. Bell, et al. 
 2014 An Integrated Epigenomic Analysis for Type 2 Diabetes Susceptibility Loci in Monozygotic 
Twins. Nature Communications 5: 5719. 
45 
 
 
Zeggini, E. 
 2007 A New Era for Type 2 Diabetes Genetics. Diabetic Medicine 24(11): 1181–1186. 
 
Zeggini, Eleftheria, Laura J. Scott, Richa Saxena, et al. 
 2008 Meta-Analysis of Genome-Wide Association Data and Large-Scale Replication Identifies 
Additional Susceptibility Loci for Type 2 Diabetes. Nature Genetics 40(5): 638–645. 
  
46 
 
7 Figures Legend 
 
Figure 1 Workflow of Infinium HTS Assay ______________________________________________________________ 9 
Figure 2 Overview on EpiTYPER assay ______________________________________________________________10 
Figure 3 Manhattan plot of all SNPs for the association analysis of two comparisons. __________________________ 13 
Figure 4 Heatmap of Pearsons’ correlation among selected variables. _______________________________________ 26 
Figure 5 Accuracy score based on number of covariates included. __________________________________________ 29 
Figure 6 Graphical view of prediction model results. _____________________________________________________ 30 
Figure 7 PLS analysis of the results of the first prediction model. ___________________________________________ 31 
Figure 8 Scatter plot of the EpiAge of subjects as a function of their Real Age. ________________________________ 32 
 
8 Tables Legend 
 
Table 1 Subjects included in the genetic study___________________________________________________________ 7 
Table 2 Subjects included in the methylation study _______________________________________________________ 8 
Table 3 Amplified regions using for methylation analyses of TCF7L2 gene. ___________________________________ 10 
Table 4 Amplified regions using for methylation analyses of epigenetic little clock genes. _______________________ 11 
Table 5. List of SNPs with a pvalue < 10-5 in the comparison between diabetic individuals and controls._____________ 15 
Table 6 . List of SNPs with a pvalue < 10-5 in the comparison between diabetic individuals and centenarians. ________ 17 
Table 7 . List of SNPs with a pvalue < 10-4 showing association in the two comparisons. _________________________ 18 
Table 8 List of SNPs with a pvalue < 10-4 showing association in the two comparisons with more than one variant. ___ 19 
Table 9 Genes showing multiple association with p value<10-4 in the two comparisons and their functions. _________ 21 
Table 10 Genes with multiple association (p value<10-4 ) shared in the two comparisons and their functions. ________ 22 
Table 11 Regions considered for methylation analysis. ___________________________________________________ 23 
Table 11 CpG sites with a significant different methylation levels in T2D individuals and controls _________________ 24 
Table 12 CpG sites with a significant different methylation levels in three genotypes groups _____________________ 25 
Table 13 Means and standard deviations of the coefficients obtained from the 50 iterations for the first prediction 
model. ________________________________________________________________________________________ 28 
Table 14 Slope and r2 values resulted from linear regression model. ________________________________________ 32 
 
